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ABSTRACT 
Histophilus somni is an economically important member of the bovine respiratory disease 
(BRD) complex. An H. somni infection has a number of clinical manifestations including 
septicemia, myocarditis, pneumonia, bronchopneumonia, arthritis and infectious thromboembolic 
meningoencephalitis. The incidence of systemic disease has significantly increased over the past 
decade while respiratory disease incidence has remained constant. Current vaccines based on 
decades old strains are less effective against the systemic form of disease. 
An understanding of the immune responses generated as well as the antigens expressed 
during infection is essential in producing effective vaccines. TonB-dependent proteins have been 
shown to be protective in other members of the Pastuerellaceae family. Therefore, I hypothesized 
that vaccination with H. somni TonB-dependent proteins would be protective against experimental 
infection and a good cellular immune response would be induced following immunization.  
The genes coding for the TonB-dependent receptor 1372, transferrin-binding protein 1 
(Tbp1) and transferrin binding protein 2 (Tbp2) also known as TbpA and TbpB respectively, were 
cloned, expressed and protein products purified. Vaccine formulations containing all three proteins 
were tested in mice to determine the Th1/Th2 response. These results showed that Tbp2 induced 
an increase in the production of IFNγ, a cytokine of the cellular immune response. ELISAs and 
proliferation assays were used to evaluate whether experimentally infected cattle immunized with 
the three proteins generated both humoral and cellular immune responses. Results suggested that 
TonB-dependent receptor 1372 initiates both a proliferative response and a humoral response 
while Tbp1 and Tbp2 induce a cellular and humoral immune response, respectively, in cattle.  
This work provides a better understanding of the immune responses generated against H. 
somni infection and aids in the development of a vaccine capable of preventing both respiratory 
and systemic disease. 
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1.0 INTRODUCTION 
Histophilus somni (H. somni), previously known as Haemophilus somnus, is an 
economically important pathogen. It is a component of the Bovine Respiratory Disease 
complex and has a large impact on the cattle industry in North America. H. somni infection is 
the leading cause of economic loss in fall-placed feedlot calves in Alberta. Disease symptoms 
include myocarditis, septicemia, bronchopneumonia, arthritis, pericarditis and pleuritis. 
This pathogen is able to cause both local and systemic disease with the incidence of systemic 
infection increasing over the past decade.  
Existing vaccines are ineffective at protecting against the systemic form of the disease 
that includes myocarditis, pleuritis and arthritis. Commercially-available vaccines are 
composed of killed whole cells using strains isolated decades ago; however, there is one 
exception that is a bacterial extract vaccine that includes in-vivo expressed antigens such as 
iron-regulated outer membrane proteins. These proteins are TonB-dependent and function 
as part of the TonB-dependent transport system. This system is common to most Gram-
negative organisms and is involved in the acquisition of iron from the host. 
 I hypothesized that vaccination with these TonB-dependent proteins produced by H. 
somni would be protective against experimental infection and that a good cellular immune 
response would be induced. Characterization of the immune responses to H. somni TonB-
dependent proteins would aid in the selection of potential vaccine candidates. These can 
then be used in the formulation of a vaccine to provide protection against the respiratory 
and systemic forms of the disease. This could have a significant impact on the cattle industry 
by lowering the cost of treatment and mortality to cattle producers in North America. 
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2.0 LITERATURE REVIEW 
2.1 Bovine Respiratory Disease 
2.1.1 Pathogenesis 
Bovine Respiratory Disease (BRD) is the leading cause of death and economic loss to the 
cattle industry worldwide resulting in estimated losses of $800-900 million per year in the United 
States [1-5]. It results in 70-80% of morbidity and 40-50% mortality in Unites States’ feedlots [5]. 
BRD is a multifactorial syndrome where a number of agents such as bacteria and viruses as well 
as the presence of stressors, combine through complex interactions to cause disease [6, 7]. 
Stressors include weaning, transportation, overcrowding, harsh weather, pregnancy, compromised 
host immune system and exposure to multiple pathogens. These factors contribute to the 
occurrence of BRD due to infiltration of bacterial organisms into the lungs following stress or viral 
infection [1, 7-9]. The disease likely begins when a viral infection weakens the calf’s immune 
system [3, 7]. This infection may result in damage to the respiratory mucosa and modification or 
suppression of the host immune responses promoting a secondary bacterial infection by the 
opportunistic pathogens described below resulting in bronchopneumonia [1, 3, 7-10]. 
2.1.2 Bovine Respiratory Disease Pathogens 
H. somni is among the bacterial pathogens associated with BRD [6, 7, 11, 12]. It plays an 
important role in feedlot disease along with other bacteria such as Mycoplasma bovis, Mannheimia 
haemolytica and Pasteurella multocida. Many viral agents also play a role in BRD including 
bovine herpesvirus 1 (BoHV-1), bovine viral diarrhea virus (BVDV), parainfluenza 3 virus (PI3V) 
and bovine respiratory syncytial virus (BRSV) [1-3, 6, 7]. Due to the multiple factors involved in 
BRD, agents isolated in individual cases can be quite variable. The most common bacterial 
pathogen associated with BRD infections is M. haemolytica that is often found in mixed infections 
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with M. bovis and BVDV [2]. Mannheimia haemolytica, P. multocida and H. somni are commensal 
organisms of the upper respiratory tract and become pathogens in the lungs during suppression of 
the immune system due to previously mentioned stressors [2, 7]. There are many studies that 
examine each pathogen, however it is still often difficult to identify the causative agent due to the 
complexity and variability of BRD and it continues to be a major cause of financial loss to the 
cattle industry [3, 7, 13, 14].  
2.1.3 Economic Impact 
BRD is an important cause of economic loss in the dairy and beef cattle industries [3, 6, 7, 
15, 16]. The costs of BRD medical treatment are substantial and have an impact on the carcass 
merit and meat quality increasing losses due to reduced meat yield and increased mortality [2, 4]. 
In the United States, BRD has been estimated to cost the livestock industry $800 to $900 million 
per year due to death, reduced feed efficiency and treatment costs [4]. Specific losses per treated 
calf have been estimated at $23.60 [7]. There have been recent technological, biological and 
pharmacological advances to fight BRD including vaccines that are important in preventing 
economic loss however, BRD continues to be a burden on the cattle industry [6].  
2.1.4 Control of Bovine Respiratory Disease 
There are vaccines available that target different viral and bacterial agents associated with 
BRD. Commercially available vaccines for BRD commonly include BVDV, BoHV-1, PI3V and 
BRSV [17]. Unfortunately, vaccination has shown inconsistent efficacy against some bacterial 
agents such as M. haemolytica, P. multocida, and H. somni [2, 7]. This inconsistent efficacy has 
resulted in the use of antimicrobials as the primary source of management. Antimicrobials can be 
effective in reducing the incidence of BRD in large feedlots that explains why 20-50% of new 
arrivals in western Canada receive injectable metaphylactic antimicrobials as a preventative 
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measure [2]. This antimicrobial use raises concerns of driving the evolution, persistence and spread 
of antimicrobial resistance in livestock pathogens as well as commensal organisms [2]. If 
widespread resistance were to occur in BRD pathogens, the economic losses to the cattle industry 
would become very severe [2].  
There are management factors that can increase the risk of BRD. For example, calves 
purchased from sale barns will have a higher risk of developing BRD due to the increase in 
transportation, marketing and mingling with animals from other farms [13]. The introduction of 
purchased calves involves activities such as dehorning, castrating, administration of vaccines, 
growth promoting implants and abortion of any pregnant heifers which can all result in an increase 
in stress [13, 14]. Since there has been no success in finding processing practices that eliminate 
BRD, preconditioning measures have been identified for pre-shipment of calves. Common 
components of preconditioning include: vaccination for respiratory viruses and sometimes bacteria 
such as M. haemolytica, P. multocida and H. somni; dehorning and castration with adequate 
healing time; weaning prior to shipment; training calves to eat and drink from troughs. The goal is 
to eliminate stressors happening over the course of days and instead allowing days or weeks for 
the calves to adjust [14]. Unfortunately, the results of preconditioning studies are difficult to 
interpret because  on-farm morbidity during preconditioning is often not reported. Therefore, BRD 
may not be reduced and instead the disease is postponed to occur with the cow-calf producer [14].  
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2.2 General Immunology 
2.2.1 Innate Immune Response 
Innate immunity is the first line of defense and it recognizes foreign material such as the 
nucleic acids, carbohydrates and proteins of pathogens that are not produced by the host. This 
recognition of foreign material is dependent on pattern-recognition receptors (PRRs) such as Toll-
like receptors (TLRs), C-type lectin-like receptors and cytosylic Nod-like receptors that are 
capable of sensing a wide range of microbial stimuli such as pathogen-associated molecular 
patterns (PAMPs) [18, 19]. Innate immunity consists of elements that are always present such as 
the skin and mucous membranes that present physical barriers and chemical components such as 
pH,  fatty acids and antimicrobial peptides [20]. These components, that are always present, enable 
the innate immune response to respond quickly and efficiently due to the presence of PRRs on the 
epithelial cells and innate cells circulating the body [21]. Other components of innate immunity 
include phagocytic cells such as neutrophils and macrophages, dendritic cells (DC), natural killer 
(NK) cells and serum proteins such as the components of the complement system, β-lysin, 
lysozyme and mediators of inflammation [19, 22]. All of these elements participate in either the 
destruction of pathogens or in increasing the effectiveness of host reactions by inducing adaptive 
immunity [20]. 
Histophilus somni can be found living as a commensal organism in the upper respiratory 
tract of cattle. During stress such as viral infection, transportation or weaning H. somni causes 
disease by adhering to nasal and respiratory epithelial cells [23]. How this pathogen adheres to 
epithelial cells is not yet defined, however it may involve heparin-binding motifs. Heparan sulfate 
proteoglycans coat the endothelial cells and form a charged layer that plays a role in 
anticoagulation [23]. Histophilus influenzae is known to adhere to human respiratory epithelial 
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cells, cause focal damage to respiratory mucosa and adhere to damaged cells [23]. Evidence 
suggests a connection between increased adherence and cell damage but there is no evidence of 
damage to the epithelial cells during H. somni infection. Perhaps damage is caused by other 
pathogens such as the viral components of BRD previously discussed [23]. Interaction with 
epithelial cells results in the stimulation of PRRs present on epithelial cells and innate cells such 
as neutrophils and macrophages [24]. These receptors sense microorganisms by recognition of 
PAMPs such as microbial proteins, lipids, carbohydrates and nucleic acids [24]. Recognition leads 
to the production of inflammatory cytokines, chemokines and type I interferons. Many types of 
PRRs exist including the well-studied TLRs mentioned previously, which are capable of detecting 
microbial nucleic acids, lipoproteins, lipopolysaccharide and flagellin [24, 25]. These receptors 
modulate the immune responses including cytokine signaling and secretion, phagosome 
maturation, nod-like receptor (NLR) activation and autophagy. Another important PRR is the NLR 
that detects bacterial molecules in the cytoplasm of cells, works synergistically with TLR 
activation and triggers inflammatory cytokine secretion [24, 25]. In order to cause systemic 
disease, H. somni must be capable of crossing the epithelial barriers that separate the inner and 
outer lung however, how is unknown. Many possibilities exist such as direct transmigration, the 
use of infected leukocytes as a Trojan horse, induction of apoptosis or necrosis, coagulation that 
increases vascular permeability, and other mechanisms that result in compromised function of the 
epithelium [23].  
In order to infect leukocytes and possibly travel systemically via these infected cells, H. 
somni must be capable of surviving intracellularly. While acting as antigen presenting cells for 
activation of lymphocytes, macrophages patrol the body and engulf pathogens into a vacuole 
where they are able to direct high concentrations of reactive oxygen species, reactive nitrogen 
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intermediates and antimicrobial peptides [25]. There is evidence that H. somni can survive and 
replicate to an extent in bovine macrophages through the inhibition of reactive oxygen and nitrogen 
intermediates. It has also been shown that neutrophils that ingest H. somni have compromised 
bactericidal activity and change in a way that is similar to apoptosis [23]. Neutrophils produce 
neutrophil extracellular traps (NETs) and while it is undefined how H. somni triggers this reaction, 
these traps are produced during an H. somni infection much like N. meningitidis and H. influenzae. 
The release of NETs is induced by activated platelets, which bind the neutrophil. The neutrophil 
then releases decondensed chromatin that forms a sticky mesh decorated with antimicrobial 
peptides such as histones, elastase, cathepsin G and myeloperoxidase [23, 26]. These traps ensnare 
pathogens like H. somni in the vasculature and help to limit dissemination [26]. 
 H. somni is capable of adhering to epithelial cells but it can also adhere to endothelial cells 
that line the blood vessels. Adherence to these cells results in the induction of inflammatory 
cytokine tumor necrosis factor-alpha (TNF-α), which also results in increased adherence [23]. H. 
somni infection often results in the formation of thrombosis, a tightly regulated reaction by a 
system of anticoagulant mechanisms that ensure homeostasis. There are three steps to initiation of 
coagulation and thrombis formation [27, 28]. When endothelial cells are injured, not functioning 
or disrupted, tissue factor is exposed to factor VIIa found in the blood and this is the initiation step. 
Factor VIIa and tissue factor form a complex that initiates coagulation by activation of factors IX 
and X, which generate factor IIa also known as thrombin. The second step, amplification, is the 
rapid production of thrombin to form a stable clot. This leads to the third step, propagation, where 
recruitment of activated platelets to the site of injury takes place. These platelets provide the 
mediators for optimal generation of thrombin that leads to the production of fibrin from fibrinogen 
to make a stable blood clot [27, 28]. Many of these innate responses that are induced during H. 
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somni infection result in the activation of the adaptive immune response. For example, innate cells 
such as neutrophils, dendritic cells and macrophages will continue to patrol the body and act as 
APCs to lymphocytes by presenting antigenic peptides in the lymphnodes. The stimulation of 
cytokines and chemokines also induces the pathogen-specific and long-lasting memory provided 
by B and T cells of the adaptive immune response [26-28]. 
2.2.2 Adaptive Immune Response 
The adaptive immune response requires stimulation by exposure to a pathogenic microbe 
and its magnitude and capabilities increase with each exposure to a particular antigen [21]. This 
means that the adaptive immune response is more specific than innate and involves memory [20, 
21]. The components of adaptive immunity include but are not limited to lymphocytes, secretion 
of antibodies, secretion of cytokines that regulate and coordinate the activities of both the innate 
and adaptive immune cells and chemokines that regulate cell migration and movement to tissue 
sites [20, 21].  There are several types of immunity including Th1, Th2, Th3, Th17 and others. 
However, the two most important types of adaptive immunity are cell-mediated and humoral 
immunity or Th1 and Th2, respectively [20, 21, 29]. T cells mediate cell-mediated immunity, 
which is required to combat intracellular microbes, such as H. somni, as they are inaccessible to 
circulating antibodies [21]. T lymphocytes promote killing of infected cells, cooperate with B cells 
to enhance production of effective antibodies, induce inflammatory responses and regulate 
immune responses [20, 21]. Antibodies present in blood and mucosal secretions mediate humoral 
immunity [20, 21]. The antibodies recognize microbial antigens or their toxins and neutralize or 
mark them as targets for elimination. Antibodies are also capable of activating mechanisms such 
as phagocytosis and the release of inflammatory mediators while also providing defense to 
mucosal surfaces and newborns [21].  
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When adaptive immunity is involved in controlling an infection, APCs such as dendritic 
cells and macrophages are located in the epithelia and connective tissues where they capture 
microbes, digest proteins and move to the lymph nodes to present antigens to lymphocytes [21, 
22]. The digested protein fragments are expressed via either class I or class II major 
histocompatibility complex (MHC) molecules on the surface of the cell and are presented to naïve 
T cells in the lymph nodes [29]. T cells can be functionally divided into helper T cells and cytotoxic 
T cells, or CD4+ and CD8+ respectively. Both helper T cells and cytotoxic T cells are MHC 
restricted as CD4+ T cells recognize antigenic peptides presented on MHC class II while CD8+ T 
cells recognize peptides presented on MHC class I [29]. The differentiation of the adaptive immune 
response towards a Th1 cell-mediated response or a Th2 humoral response depends on the 
activation of helper T cells. The activation of T cells requires three signals. The first signal is the 
binding of the T-cell receptor (TCR) to an antigen-MHC complex. Costimulatory molecules 
provide the second signal and cytokines provide the third [29, 31]. Costimulatory molecules 
include but are not limited to CD28, OX40, ICOS and TIM-1 [29]. Upon activation, helper T cells 
differentiate into effector and memory T cells that produce and secret cytokines that drive the 
proliferation of T helper cells, activate B cells and induce the differentiation of cytotoxic T cells 
into CTLs that recognize and lyse infected self-cells [29].  
Cytokines are molecules produced during the innate immune response and are important 
costimulators. The major cytokines secreted by PAMP-stimulated cells act on both B and T 
lymphocytes and include IL-12, IL-1, IL-6, IL-23, IL-15 and IL-6. The cytokine IL-12 stimulates 
the CD4+ T cells to differentiate into Th1 effector cells. Cytokines IL-1, IL-6 and IL-23 stimulate  
them to differentiate into Th17 helper cells [21]. T lymphocytes that are CD8+ differentiate into 
cytotoxic T lymphocytes (CTLs) that patrol the body and recognize and lyse infected host-cells. 
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Survival and memory of these CD8+ T cells, which are both important for immunity and long-term 
infection, are promoted by IL-15. [20-22]. These CTLs are involved in the cellular or Th1 response 
and are key in combatting intracellular pathogens [18, 29].  
Differentiated B cells result in the production and secretion of different classes of 
antibodies, promoted by IL-6, that are involved in the humoral or Th2 response. Different classes 
of antibodies perform specialized functions that are each important in humoral immunity. These 
classes include the isotypes IgA, IgE, IgM and IgG [21]. Isotype IgA plays a primary role at 
mucosal surfaces where it is actively secreted across the epithelial barrier. IgE is primarily 
involved in anti-parasitic and hypersensitivity reactions while IgM is a serum-antibody and a naïve 
B cell antigen receptor. IgG is the primary serum-antibody involved in opsonisation, activation of 
the complement cascade and neonatal [21].  
Passive immunization is a method of transferring antibodies from one individual to another. 
It has been shown that calves can be protected from H. somni through passive immunization [23]. 
More specifically, IgG2 appears to be more protective than IgG1, IgM and IgA as the levels of 
IgG2 peak later and last longer post-infection [23, 30]. IgA is thought to be important for mucosal 
surfaces and shows an increase during H. somni infection however, as IgG2 levels increase, IgA 
levels as well as the levels of H. somni decrease. Perhaps IgA is blocking epitopes that are 
important for IgG2 opsonization and this limits the protection that is provided by opsonisation of 
H. somni bacteria by IgG2 [23]. H. somni has proven capable of evading these immune responses 
through mechanisms such as interfering with phagocyte function, shedding of antigens that bind 
antibodies, decreased immune stimulation and antigenic variation, allowing infection to persist 
[30]. 
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It is possible to analyze Th1 and Th2 responses through the detection of specific cytokines 
secreted by cells involved in each response. For example, Th1 responses can be determined by 
analyzing Interferon-gamma (IFN γ) or Interleukin-2 (IL-2) levels, while Th2 responses can be 
determined by analyzing levels of Interleukin-4 (IL-4) or Interleukin-5 (IL-5) (Refer to Figure 2-
1) [29]. 
2.2.3 Vaccines and Adjuvants 
Vaccines have been used for centuries and offer an effective and cost-efficient means of 
providing protection against infection [18, 19, 31]. Vaccines are killed or attenuated forms of an 
infectious agent that is administered to healthy individuals to elicit an immune response [19, 21]. 
This immune response provides the individual with protection against the live, pathogenic microbe 
[21]. As described above, the innate immune system is a key component in sensing foreign 
substances such as vaccines and adjuvants that stimulate the development of a protective response 
[18]. There are many types of vaccines, including attenuated, inactivated vaccines, subunit 
vaccines, DNA vaccines and recombinant vaccines [21]. Live attenuated vaccines are composed 
of weakened versions of virus or bacteria that induce immunity similar to the protection gained 
from a natural infection [18, 21]. Inactivated vaccines contain killed pathogens and often require 
adjuvants in order to elicit a strong enough immune response [31]. The subunit vaccines can 
include purified antigens, toxins and carbohydrates along with adjuvants, which enhance and 
modify the immune response induced. Some subunit vaccines contain bacterial polysaccharides 
coupled to proteins to form a conjugate vaccine, which elicits a high-affinity antibody response 
[18, 21, 31]. Most vaccines induce the production of neutralizing antibodies. These antibodies are 
useful in neutralizing pathogens such as toxin-secreting bacteria and their toxins, blood-borne 
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viruses and mucosal viruses and can be measured with assays that measure functional antibody 
activity such as an enzyme-linked immunosorbent assay (ELISA) [18].  
Adjuvants were first described in 1924 as “substances used in combination with a specific 
antigen that produced a more robust immune response than the antigen alone” (Ramon, 1924) 
[31, 32]. Adjuvants are used because they stimulate a stronger, faster and longer lasting immune 
response. They also allow the modification or directing of the immune response as they can be 
used to specifically enhance either the antibody or the cellular immune response [31]. Adjuvants 
can be composed of many different substances including but not limited to oils, virosomes, TLRs, 
monophosphoryl lipid A (MPL), unmethylated CpG dinucleotides and heat-killed bacteria [19, 
21]. A mineral salt adjuvant, Alum is the oldest adjuvant and has been used successfully in animal 
and human vaccines since the 1940s [19, 31, 32]. Adjuvants can help vaccines become more 
immunogenic in many ways. They can induce a protective immune response earlier, which is 
important during an outbreak. They can reduce the number of immunizations as well as the amount 
of vaccine material necessary. Adjuvants can also elicit protection in the young and the elderly 
and allow vaccination through new routes such as mucosal membranes [31]. The mechanisms of 
action of adjuvants are not completely understood however, it is known that they are capable of 
using one or more mechanisms. Some of these mechanisms include acting as a signal of danger, 
forming a depot at the site of infection and activation and maturation of APCs [31, 32]. The 
adjuvant is recognized by the PRRs present on APCs and this recognition informs the immune 
system that there is an ongoing event or danger present and as a result, the innate immune response 
is up regulated. Subsequent activation of the adaptive immune response is also initiated however; 
the type of adaptive response mounted depends on the danger signal [31]. When the adjuvant forms 
a depot at the site of injection, the antigen is absorbed to the adjuvant and this allows for the slow-
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release of antigen to ensure constant stimulation of the innate immune response [31, 32]. As the 
APCs arrive at the site of injection, they take up the vaccine, process, and present peptides to helper 
and cytotoxic T cells. As mentioned above, activation of these T cells requires the presence of a 
costimulatory molecule which depends on the danger signal itself. Therefore, adjuvants are 
capable of influencing the type of immune response that is induced [31, 32]. 
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Figure 2-1 Summary of Th1 and Th2 immune response development. Transcription factors T-
bet and GATA-3 are essential for the development of both Th1 and Th2 responses, respectively. 
Cytokines are released directing T-helper cell differentiation. Cytokines secreted by Th1 cells are 
IFNγ and IL-2, while cytokines secreted from Th2 cells are IL-4 and IL-5. Adapted from Abdoli 
et al. 2015.  
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2.3 Histophilus somni 
2.3.1 Characteristics and Significance 
Histophilus somni is a Gram-negative coccobacillus, non-encapsulated and non-motile 
member of the Pasterellaceae family. It does not have pili or flagella and does not form spores [3, 
6, 9, 12, 33-35]. H. somni is an intracellular pathogen that shows strict host-specificity in 
ruminants, most notably in cattle [6, 36]. The disease has a large economic impact on the livestock 
industry but more specifically the cattle industry [34, 35]. H. somni is described as an opportunistic 
and facultative intracellular pathogen that under normal circumstances is relatively non-invasive 
[6, 10, 12, 33, 37]. It is a part of the microflora of the lower reproductive tract as well as the 
mucosal surfaces of the upper respiratory tract of cattle and other ruminants [3, 6, 9, 12, 16, 33]. 
During the presence of stressors such as overcrowding, viral infection and transportation, H. somni 
is capable of causing disease [9, 12]. Identification of H. somni can be difficult due to its fastidious 
growth conditions as well as the fact that it is often found alongside other bacterial pathogens such 
as M. haemolytica, P. multocida, or T. pyogenes [2, 36]. Often, these other organisms result in H. 
somni not being isolated from culture due to their overgrowth [2].  
2.3.2 Virulence Factors 
H. somni has a variety of virulence factors that have been explored since its first isolation 
in 1956 [9, 16, 34, 36]. These include adherence factors, phase variation of surface proteins, 
lipopolysaccharide (LPS) and lipooligosaccharides (LOS), outer membrane proteins, serum 
resistance, biofilm formation and iron-binding proteins [3, 9, 12, 34-36, 38]. These H. somni 
virulence factors allow it to protect itself from host defences, induce inflammation, damage and 
evade the immune system and promote colonization of various tissue sites [9, 38]. The virulence 
factors cause many negative effects on the host, such as apoptosis of bovine endothelial cells, 
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platelet aggregation, pro-inflammatory response, intracellular survival and activation leading to 
endothelial cell death [3, 9, 16]. H. somni also produces proteins capable of binding the Fc region 
of immunoglobulin [9, 12, 38, 39]. These proteins known as immunoglobulin binding proteins 
(IgBPs) are able to bind to antibodies such as Immunoglobulin G2 (IgG2) [3, 9, 12, 34, 35, 39-41]. 
The non-specific binding of these proteins to antibodies prevents antibody-mediated inactivation 
of H. somni [9, 35]. Transferrin-binding proteins (Tbps) have also been identified in H. somni. 
These proteins are responsible for scavenging iron from the host and may be another factor 
effecting virulence and host immunity [9, 12, 35, 38]. The acquisition of iron and other nutrients, 
attachment to host cells, and interactions with phagocytic cells are among H. somni’s other 
virulence-associated factors that result in the modification of phagocytic cell function and 
therefore the modification of host immunity [34]. 
2.3.3 Pathogenesis 
H. somni infection is represented by various symptoms such as septicemia, infectious 
thrombotic meningoencephalitis (ITME), polyarthritis, myocarditis, bronchopneumonia, 
pneumonia, and pleuritis [3, 12, 15, 33-35, 38, 40-45]. As mentioned above, bacterial colonization 
occurs after a viral infection suppresses the immune system and H. somni moves into the lower 
respiratory tract [1, 3, 7-10, 30]. H. somni is capable of colonizing the surfaces of mucosal 
membranes and attaching to non-epithelial cells [36]. It protects itself in host tissues, especially 
during colonization of the heart through the formation of a biofilm. This biofilm protects the 
organism from host immune responses and antibiotics [34].  H. somni is able to gain entry into the 
bloodstream where it is able to internalize in immune cells and disseminate to various areas of the 
body such as the brain, heart, skeletal muscle, joints, kidneys and liver [36, 42, 45]. Septicemia 
and localization in the heart and joints has occurred with increased frequency since the late 1980s. 
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The occurrence of ITME is less frequent while more myocarditis and arthritis are reported [42, 
44]. This may be due to the adaptation of H. somni to the increased use of vaccines and mass 
treatment with antibiotics [42, 44, 45]. However, strains with different virulence factors may have 
evolved through natural selection and while the organism changed, the immune responses of the 
host population varied [42]. 
Myocarditis occurs more in yearlings than in weaned calves who appear either chronically 
ill or perfectly healthy before they die suddenly [42, 45]. The cause of death is acute heart failure 
accompanied by evidence of pulmonary congestion and edema [42]. Localization in the heart 
results in infarction, inflammation and lesion formation (Figure 2-2A) resulting in cardiac failure 
and death [45]. Arthritis is also a major symptom of current H. somni infection. Multiple joints are 
affected (Figure 2-2B) and the animals show signs of stiffness, lameness, and knuckling at the 
fetlocks. At necropsy, affected joints show obvious infection through excessive fluid accumulation 
and the presence of fibrinous clots [42]. 
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Figure 2-2: Myocarditis and arthritis resulting from H. somni infection. (A) The myocardial 
lesions formed during infection. (B) Arthritis with swelling and fluid-filled joint.   
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H. somni shows resistance to intracellular killing, observed by an abundance of bacteria in 
phagocytic cells, such as macrophages and neutrophils, within diseased organs. Neutrophils are 
able to internalize the bacteria but are ineffective at killing it as the cells remain viable within the 
vacuole [9, 36]. It has been shown that neutrophils isolated from cattle infected with H. somni have 
exhibited decreased anti-bacterial activity [30]. By surviving within phagocytic cells, H. somni is 
capable of avoiding other host defenses and invading various tissues, which likely contributes to 
the development of a chronic, multisystemic infection [36]. Incubation of H. somni with alveolar 
macrophages, blood monocytes and neutrophils decreases their ability to phagocytose as well as 
their ability to produce oxygen-free radicals and kill bacteria [16]. When cultured with bovine 
blood monocytes, H. somni has the ability to survive and multiply even when the immune cells are 
treated with cytokines, which demonstrates H. somni’s ability to avoid killing by macrophages 
[37]. These infected macrophages serve as a depot for infection that may explain in part, the 
subacute to chronic course of the infection [37]. Survival within mononuclear phagocytes is a 
strategy that many other pathogens have developed, including Mycobacteria, Brucella, 
Salmonella, Yersinia and Listeria [37]. By surviving within phagocytes, H. somni  is able to protect 
itself from the immune system, spread throughout the body and cause both local and systemic 
disease [8, 10, 11, 16, 36, 37].  
2.3.4 Immunity to H. somni infection 
The interaction of H. somni with the host innate immune system begins with evading the 
neutrophils. As described above, H. somni is adept at avoiding neutrophil killing and it has been 
discovered that H. somni is capable of altering neutrophil activity once ingested [30]. Mononuclear 
phagocytes also show limited ability to kill H. somni, which appears capable of surviving and 
replicating within bovine monocyte-derived and alveolar macrophages. H. somni, both in its free 
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form as well as intracellular form, will interact with the endothelium of the blood vessel walls. H. 
somni adheres to the endothelial cells and activates nearby cells that release the inflammatory 
cytokine tumor necrosis factor alpha (TNF-α) [30]. 
The methods of controlling H. somni infection are vaccination, mass treatment with 
antibiotics, and vaccination against other BRD pathogens [30]. There are commercially available 
vaccines that specifically target H. somni however; they were developed from strains isolated in 
the 1970s. These vaccines were developed to address the nervous system form of the disease, 
ITME. ITME was the only clinical form of the disease recognized during the 1970s [9, 10, 42]. 
Since then other disease conditions were becoming more common and new manifestations of the 
disease were being reported [42]. During the 1990s, haemophilosis was recognized as a significant 
cause of mortality, along with myocarditis and arthritis, in fall-placed feedlot calves in western 
Canada [44].  
There are 26 USDA-approved vaccines developed for the American market that target H. 
somni and are heavily used however, their ability to provide a protective immune response is 
modest or unknown [30]. Many currently available vaccines utilize killed whole cell bacterins that 
have been relatively successful in reducing the risk of ITME [35]. These whole cell vaccines 
however, do have a reputation for occasionally causing severe side effects and do not provide 
protection, which is why the development of new vaccines is necessary [41]. Subunit vaccines 
provide a way around the problems often caused by killed whole cells. One such vaccine is the 
currently available Somnu-Star PH (Elanco Animal Health), an acellular vaccine containing in-
vivo expressed proteins. These proteins include iron-regulated outer membrane proteins, obtained 
from cultures of H. somni, which aid in reducing inducing a protective immune response against 
BRD [35, 46, 47]. It is possible that these currently available vaccines are not effective against H. 
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somni when it is in a biofilm but only protects against planktonic cells, another reason more 
research and vaccine trials are necessary [34].  
2.4 TonB-dependent Proteins 
2.4.1 TonB-dependent Transport System 
Iron is an essential nutrient for all organisms but it is not readily available under normal 
conditions in the host [48-51]. Iron is a component of erythrocytes and bound to haemoglobin, 
hemopexin or haem. Since iron-binding proteins such as haemoglobin, transferrins, lactoferrins 
and ferritins chelate iron, it is not readily available to pathogens [49, 52-54]. Transferrins have an 
N and a C lobe that are each able to bind ferric iron and sequester it from pathogenic organisms 
that have developed countermeasures to acquire iron [52, 54]. Iron is important to microorganisms 
since it is a key component of important metabolically-linked compounds so acquisition during 
infection is imperative to survival and replication of pathogens [49].  
Bacteria have developed many strategies that allow them to obtain iron from their host. 
Many bacteria produce low-molecular-weight iron binding ligands that have a high affinity for 
iron while others are able to utilize haem-bound iron. Serratia marcescens uses a haem-binding 
protein called a haemophore that is secreted and later taken up through the use of receptors [49]. 
Another strategy bacteria have developed involves the TonB-dependent transport system common 
to most Gram-negative organisms [50]. This transport system is regulated by the supply of iron, 
as high levels of iron can be toxic to the cell. In E. coli, the Ferric Uptake Regulator (Fur) regulates 
the expression of genes involved in iron such as transferrin-binding proteins (TBPs). When iron 
levels are high, the Fur repressor binds the DNA sequence called the Fur box using Fe2+ as a 
cofactor. The binding of the Fur repressor to the box represses transcription of genes involved in 
the uptake of iron [50]. During iron-depleted conditions, the TonB-dependent outer membrane 
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proteins are synthesized in large amounts and their activity increases [51]. Iron is acquired by 
either direct binding to bacterial outer membrane proteins or by the release of siderophores that 
acquire iron from host proteins and bring it back to specific TonB-dependent receptors [48, 49, 
52]. The TonB-dependent complex includes three inner membrane proteins TonB, ExbB and ExbD 
that couple the energy from the proton motive force in the inner membrane to the outer-membrane 
[48-51]. This energy allows the outer membrane proteins to actively pump siderophores into the 
periplasm [48]. There are many other key players involved in the TonB-dependent transport 
system, as it is a complicated process. It is energy expensive and requires energy derived from a 
proton motive force across the inner membrane [50].  
2.4.2 TonB-dependent receptor, Tbp1 and Tbp2 
Most Gram-negative bacteria have TonB-dependent transporters involved in the 
acquisition of various important substrates such as iron, vitamin B12, nickel, and carbohydrates 
[50]. The number of these transporters present in each organism varies. For example E. coli 
produces 7, Pseudomonas aeruginosa produces 34 and Caulobacter crescentus makes 65 different 
TonB-dependent transporters, whose regulation is not yet known [50]. In H. somni, the TonB-
dependent receptor is a heme/hemoglobin receptor family protein along with three other members 
of the group. Tbp1 also known as TbpA is a lactoferrin and transferrin receptor protein while Tbp2 
also known as TbpB is a transferrin-binding protein [34].  
Members of the families Neisseriaceae, Moraxellaceae and Pasterellaceae such as 
Pasteurella multocida, Haemophilus influenzae, Neisseria gonnorrhoeae, Actinobacillus 
pleuropneumoniae and Neisseria meningitidis use a highly specific uptake system to acquire iron 
from the host transferrin  [52-63]. The components of this uptake system include two transferrin 
receptors, TbpA and TbpB; a periplasmic protein dependent transport system including FbpA, 
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FbpB and FbpC; and the third component is the energy transduction system consisting of TonB, 
ExbB and ExbD [58]. TbpA and TbpB are located on the cell surface of the pathogen and interact 
directly with serum transferrin (Figure 2-3) [50, 52].  The primary component of bacterial 
transferrin and lactoferrin receptors is TbpA. This transmembrane protein facilitates the 
acquisition and relocation of iron into the bacterial periplasm [54]. The cofactor, TbpB, is an 
accessory lipoprotein that extends from the outer membrane surface using an N-terminal anchor 
peptide. This lipoprotein is involved in the capture of host transferrin through its binding to the C 
lobe and may aid TbpA in the removal of iron from transferrin [54, 56]. Both proteins work 
together in order to bind transferrin, remove the iron and import it across the outer membrane into 
the periplasm. However, while TbpA is necessary for iron acquisition, cells missing TbpB can still 
survive in transferrin rich environments, suggesting that TbpA is capable of capturing, removing 
and relocating iron itself [56-60]. TbpA is highly conserved in Neisseria strains while antigenic 
and sequence variation of TbpB tends to be more widespread however, neither TbpA nor TbpB 
are subject to high-frequency variation [56-60]. Both TbpA and TbpB are transcribed from the 
operon tbpAB, which is regulated by the regulatory protein Fur, described above [56-60]. It has 
been shown that Neisseria gonnorrhoeae deficient in transferrin-receptors is avirulent during a 
human gonococcal infection. This supports the idea that transferrin-binding proteins from 
Pasteurellaceae and Neisseriaceae play a key role in pathogen virulence [63]. Purified TbpA and 
TbpB from Neisseria are antigenic when used in the immunization of animals and the transferrin 
receptor system is found in 100% of Neisseria gonorrhoeae clinical isolates. This along with the 
fact that it is not subject to phase or antigenic variation and appears to be necessary in Neisseria 
infection in humans, makes proteins from the transferrin receptor system ideal vaccine candidates 
[56, 59].  
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The structures of TbpA and TbpB have been studied in both Neisseria and M. hemolytica 
species and while structures have been identified, the exact functions and interactions are still not 
fully understood. TbpA is thought to be made up of features including long extracellular loops that 
are involved in the interaction with transferrin, a helix finger that may be involved in the release 
of iron and a plug domain loop that may be a sensor for ligand binding [56-59]. This structure 
forms a pore in the outer membrane where iron can pass through into the periplasm [58]. When 
TbpA is bound to transferrin, the C-lobe of the transferrin appears to be partially open via the 
separation of C1 and C2 domains. The α-helix and N-terminal plug domain of TbpA are inserted 
between the separated C1 and C2 domains of the C-lobe. This suggests that the α-helix and plug 
domain are involved in the removal of iron from the transferrin [56]. TbpB is a surface-exposed 
lipoprotein that appears to increase the efficiency of iron acquisition by binding to transferrin and 
saturating it on the cell surface. It also appears to aid in the release of transferrin once iron has 
been removed and it may also participate in the extraction of iron from transferrin [56, 57, 59]. 
The binding of TbpB to transferrin is different from the binding of TbpA in that the transferrin is 
fully closed. This explains the strong preference TbpB has for binding to iron-bound transferrin 
[56]. Currently, there is a model of iron-transport which involves the binding of transferrin to TbpB 
followed by TbpB bringing the transferrin to TbpA. Once TbpA binds the transferrin, iron is 
removed and imported into the cell (Figure 2-3) [59]. Evidence has suggested that antibodies to 
the loop of TbpA, a presumed key component of the protein, interrupt protein function. Cash et al. 
demonstrated that loop-specific antibodies lead to modest inhibition of TbpA function [57]. 
Vaccines have been developed to test the antigenicity of Tbps from both M. haemolyitca 
and Actinobacillus pleuropnaumoniae. Rossi-Campos et al. showed that vaccination with a 60 kDa 
transferrin-binding protein from Actinobacillus pleuropnaumoniae serotype 7 resulted in an 
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increase in antibody titres, less extensive lung damage and significantly reduced mortality in pigs. 
They also showed that this transferrin-binding protein was not protective against other A. 
pleuropneumonia serotypes, which was expected as serotypes 1 and 7 were known to express 
different 60 kDa proteins [64]. Vaccines against M. haemolytica have often been bacterins but they 
were found to have no beneficial effect, a detrimental effect or their efficacy was simply questioned 
[65]. Once it was realized that the protein produced during logarithmic growth, leukotoxin (Lkt), 
was important in the pathogenesis of M. haemolytica, the production of subunit vaccines began in 
earnest [65]. Many other antigens were identified and incorporated into subunit or subunit-
enriched vaccines, however the most important for this study were the proteins expressed in iron-
limiting environments [65]. During iron-restricted conditions, M. haemolytica is known to produce 
iron-regulated outer membrane proteins (IRP) that are absent or weakly expressed in iron-rich 
conditions [55, 66, 67]. In the 1990s, it was documented that sera from recovered, experimentally 
infected, sheep contained antibodies specific for these IRPs [67]. The presence of specific 
antibodies suggested these were protective antigens [67]. Since then, inactivated vaccines 
containing these IRPs have been more frequently developed to combat BRD and shown to provide 
protection six weeks after the first immunization [68]. A study by Potter et al. looked at the effect 
on antibody titres when calves were immunized with M. haemolytica’s TbpB and TbpA [63]. 
Calves that received TbpA showed an insignificant increase in antibody titres, while calves 
immunized with TbpB showed a signficant increase in antibody titres specific for TbpB. When 
calves were immunized with both proteins, there was no evidence of a significant TbpA-specific 
antibody response however, TbpA did aid in the overall health of the calves possibly by inducing 
a cell-mediated immune response [63]. Potter et al. also studied the effects of immunization with 
H. somni’s Tbp1 and Tbp2. Here, it was shown that calves immunized with recombinant Tbp2 
26 
 
responded with an increase in antibody titre while their response to Tbp1 was minimal, which is 
consistent with other studies of Tbp1/TbpA from other organisms [69]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3: The interaction between transferrin-bound iron and the bacterial 
countermeasures TbpA and TbpB. Pathogens H. inlfuenzae and N. gonnorrhoeae use receptor 
TbpA and its co-receptor TbpB to acquire iron during infection. These receptors transport the 
captured iron to the bacterial periplasm from the host serum. Adapted from Armitage and 
Drakesmith 2014. 
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3.0 HYPOTHESIS AND OBJECTIVES 
3.1 Hypothesis 
Understanding the immune responses generated as well as the antigens expressed during 
infection is essential in producing effective vaccines. TonB-dependent proteins have been shown 
to be protective in other species in the genus Pastuerellaceae therefore it was hypothesized that 
vaccination with TonB-dependent proteins produced by H. somni will be protective against 
experimental infection and that a good cellular immune response is important for protection. 
3.2 Objectives 
The objectives of this study were to examine the effects of vaccination with receptor 1372, 
transferrin-binding protein 1 (Tbp1) and transferrin-binding protein 2 (Tbp2) on the humoral and 
cellular immune responses of cattle during experimental infection with H. somni. The goals of this 
study were to: (1) Clone and express the genes coding for TonB-dependent proteins of H. somni, 
(2) determine whether or not experimentally-infected cattle generate both humoral and cellular 
immune reponses against TonB-dependent antigens, (3) formulate vaccines capable of generating 
balanced Th1/Th2 responses and confirm in mice, and finally to (4) vaccinate cattle and 
characterize the immune responses toward and protective capacity of the antigens. 
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4.0 MATERIALS AND METHODS 
4.1 Bacterial strains, growth conditions and plasmids 
The E.coli strains used in this study were DH5αFʼIQ [35] and M15 [35] provided by the 
laboratory collection, BL21Plys [70] provided by the lab of Dr. Scott Napper and ER2523 
provided by NEB in the pMal protein fusion and purification system (NEB, Ipswich, 
Massachusetts, USA). All E. coli cells were grown in either liquid or solid Luria-Bertani (LB) 
medium (BD Difco Laboratories, Franklin Lakes, New Jersey) with 50 μg/mL or 100 μg/mL 
Ampicillin respectively (Sigma-Aldrich, St. Louis, Missouri, USA). Both solid and liquid cultures 
of E. coli were incubated at 37⁰C with liquid cultures being agitated at 200 rpm. H. somni AVI1 
[35] provided by the laboratory collection was grown in either liquid Brain-Heart Infusion (BHI) 
(BD Difco Laboratories) or Tryptone Soya Agar (TSA) with 5% sheep blood agar (Oxoid Inc. 
Nepean, Ontario, Canada). Plates were incubated at 37 ⁰C with 5 % CO2 while liquid cultures were 
grown at 37 ⁰C in plastic flasks (Corning Inc., Corning, New York, USA) with agitation at 200 
rpm.  
The plasmids used (Table 4-1) were pGH433His provided by the laboratory collection and 
altered by Dr. C. A. Madampage for the addition of the Histidine tag (His6-tag) and pMAL-c5X 
purchased from NEB (NEB E8200S) for the purpose of Maltose-binding protein (MBP) fusion. A 
Leukotoxin (LktA) fusion plasmid pAA352, provided by the laboratory collection, was used for 
cloning of the gene coding for Tbp2. 
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Table 4-1 Plasmids used in this study 
Plasmid Genotype and Phenotype Source 
pGH433His His tag/ampR Dr. A. Potter (VIDO-Intervac) [35] 
pAA352 Lkta fusion/ampR Dr. A. Potter (VIDO-Intervac) [71] 
pMAL-c5X MBP fusion/ampR NEB 
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Figure 4-1 Plasmid map of pGH433His. Restriction sites used, BglII and NcoI, are indicated in 
red. bla: ampicillin resistance gene. 
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Figure 4-2 Plasmid map of pAA352. Restriction sites used, NcoI and BamHI are indicated in 
red. bla: ampicillin resistance gene; lktA: leukotoxin fusion gene. 
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Figure 4-3 Plasmid map of pMAL-c5X. Restriction sites used, EcoRI and HindIII, are indicated 
in red. bla: ampicillin resistance gene; malE: gene encoding the maltose-binding protein (MBP); 
lacI: gene coding for the Lac repressor; ptac: promoter.  
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4.2 Cloning and expression 
Cloning and expression of the genes coding for Receptor 1372, Tbp1 and Tbp2 was 
modified from Madampage et al. (2015). Polymerase chain reaction (PCR) amplification of all 
three genes used genomic DNA from the strain AVI1 using the primers described in Table 4-2. 
PCR was done using a PTC-100 Thermal Cycler (Bio-Rad Laboratories, Hercules, California, 
USA) and consisted of an initial denaturation at 98 ⁰C for 5 min, then 30 cycles of denaturation at 
98 ⁰C for 10 s, annealing at 63 ⁰C for 30 s, and extension at 72 ⁰C for 2 min. A final extension was 
carried out at 72 ⁰C for 5 min. The annealing temperature and extension time varied slightly for 
each gene depending on the primers (refer to Table 4-2). Once PCR was complete, fragments were 
separated on electrophoresis in a 1% agarose (Sigma-Aldrich) gel. Receptor 1372 insert DNA and 
pGH433His vector DNA were then double digested with appropriate enzymes (NEB) (Table 4-2). 
The gene coding for Receptor 1372 was cloned using the pGH433His vector. Cloning of tbp1 was 
attempted using the pGH433His, pAA352 and pMAL-c5X vectors (Table 4-2). Attempts at 
cloning tbp2 used the pAA352 and pMAL-c5X vectors (Table 4-2). Digests were incubated at 37 
⁰C for 1 hour or for 15 minutes when using high-fidelity enzymes. Electrophoresis separated the 
fragments in a 1% agarose gel then the DNA fragments were recovered via gel purification 
(Qiagen). In order to estimate the relative amount of DNA recovered, 4 μL of digested insert and 
vector DNA was separated by electrophoresis on 1% agarose. Once a concentration was estimated, 
ligation of the insert and vector DNA was done by incubation of digested DNA with 400 units of 
T4 DNA Ligase (NEB) overnight at 16 ⁰C. Ligation mixes were then mixed with competent 
DH5αFʼIQ (M15, ER2523 and BL21Plys for Tbp1 and Tbp2, refer to Table 4-2) E. coli cells while 
including a control of cells without DNA. Mixes were incubated on ice so the DNA adhered to the 
cell surface and heat shocked for 90 seconds at 42 ⁰C during which the cells took up the DNA. 
35 
 
The cells cooled on ice for 2 minutes and were incubated in LB for 1 hour at 37 ⁰C. Cells were 
harvested by centrifugation for 10 minutes at 200 rpm after which the cell pellet was resuspended 
in about 200 μL of leftover supernatant before being spread on LB-ampicillin agar to select for 
cells containing the plasmid. Viability of competent cells was checked by plating on LB agar and 
all plates were incubated overnight at 37 ⁰C.  
For all three genes, colonies positively selected from the ampicillin plates were screened 
by colony PCR and plasmid miniprep. The first screening method used was colony PCR where 16 
selected colonies were streaked on new LB-ampicillin plates. The plates were incubated overnight 
at 37 ⁰C and samples of each streak were immersed in 50 μL of H2O (Sigma-Aldrich), boiled for 
10 minutes at 95 ⁰C and used in PCR with original primers to screen for colonies containing the 
insert. The second method of screening used in this study was the alkaline lysis method of DNA 
extraction [72] using the plasmid miniprep kit (Sigma-Aldrich). Six 5 mL aliquots of each 
overnight culture were harvested by centrifugation for 15 minutes at 3,400 rpm after which the 
pellet was resuspended and lysed according to the kit directions. Supernatant was loaded onto 
columns and centrifuged 1 minute at 12,000 x g. Each column was washed with 750 μL of the 
wash solution provided in the kit, centrifuged again and further centrifuged for 2 minutes at max 
speed. DNA was eluted from the column by the addition of 100 μL H2O (Sigma-Aldrich) directly 
onto the membrane and centrifugation for 1 minute at 12,000 x g. Like elutions were pooled, 
concentrated and stored at -20 ⁰C. 
The screening of transformants containing tbp1 and tbp2 required the use of an adapted 
colony blot method [73] to screen the transformed colonies. While the transformation plates 
incubated, nitrocellulose disks (Bio-Rad) were prepared by soaking in Phosphate Buffered Saline 
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A (PBSA) (137 mM Sodium chloride, 2.7 mM Potassium chloride, 8.1 mM Sodium phosphate 
diabasic anhydrous, 1.5 mM potassium phosphate monobasic) + 0.1%  Sodium dodecyl sulfate 
(SDS) (Bio Basic, Markham, Ontario, Canada). Once soaked the disks were incubated in a 65 ⁰C 
water bath for 30 minutes to strip the membrane and make it permeable to IPTG. The disks were 
washed with ddH2O and soaked in PBSA + 10 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(Sigma-Aldrich) at room temperature for 30 minutes. The disks were dried overnight at 37 ⁰C and 
the next day, they were gently placed on the transformation plates. Without shifting the disks, they 
were immediately lifted off and placed on fresh LB-ampicillin agar with the colony side up. 
Original plates and disks were incubated at 37 ⁰C for 2 hours after which the disks were incubated 
with chloroform (Sigma-Aldrich) vapours for 15 minutes at room temperature. The cells were 
lysed with 10 mL Lysis buffer (0.1 M Tris pH 7.5, 0.17 M NaCl, 5 mM MgCl2 6H2O, 1.5% BSA 
Fraction V, 1 μg/mL DNase, 40 μg/mL lysozyme) and left overnight at room temperature with 
gentle shaking. The next day, disks were washed twice for 20 minutes in 1X Tris-buffered Saline 
(TBS) (1 M Tris base, 170 mM NaCl, pH 7.5) with gentle shaking. Once lysed, disks were wiped 
to remove cell debris and washed again with TBS. Disks were blocked for 30 minutes in 1% fish 
gelatin (Sigma-Aldrich), incubated with primary anti-MBP monoclonal antibody (NEB) diluted 
1:4 for 1 hour and washed twice in Tris-buffered Saline + 0.1% Tween 20 (TBST) with shaking. 
The disks were incubated with a 1:2 dilution of secondary goat anti-bovine AP conjugated 
antibody (KPL, Gaithersburg, Maryland, USA) for 20 minutes and washed 3 times in TBST. 
Finally, they were developed in AP buffer (0.1 M Tris pH 9.6, 0.1 M NaCl, 50 mM MgCl2 6H2O) 
with Nitrotetrazolium Blue Chloride (NBT) (Sigma-Aldrich) and 5-Bromo-4-Chloro-3-indolyl 
phosphate p-toluidine salt (BCIP) (Sigma-Aldrich), ddH2O was used to stop the reaction. Results 
were analyzed immediately after the reaction was stopped for best accuracy. 
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Transformants containing the H. somni gene of interest were further screened for protein 
expression through small-scale IPTG induction. An overnight culture of each clone was grown at 
37 ⁰C and diluted 1:10 the next day in LB-ampicillin. The diluted culture was incubated at 37 ⁰C 
until it reached an optical density (OD) of 0.6 at 600 nm and then it was split into 2 tubes each 
containing 2.5 mL of culture where one served as the uninduced control. A final concentration of 
1 mM IPTG was added to the induced sample before all samples were further incubated at 37 ⁰C 
for 2 hours to allow the cells to be induced. After the 2-hour incubation, 1.5 mL aliquots were 
transferred into Eppendorf tubes and harvested by centrifugation for 5 minutes at 13,000 rpm. 
Cells were resuspended in 120 μL of 2x sample buffer (0.25 M Tris-HCl [Sigma-Aldrich] pH 6.8, 
20% SDS, 20% Glycerol, 0.2% β-mercaptoethanol, Bromophenol Blue), boiled for 5 minutes at 
95 ⁰C and 5 μL was run on a 10% SDS-PAGE gel. Samples of induced and uninduced cells were 
also stored at -20 ⁰C. Once it was determined they were expressing the correct-sized protein, 
samples were run on duplicate SDS-PAGE gels. One gel was transferred to nitrocellulose a 
membrane (Bio-Rad) for western blotting while the other was stained. After being transferred, the 
membrane was removed and washed in 1X TBS before being incubated for 20 minutes in 1X TBS 
+ 1% fish gelatin then left at 4 ⁰C overnight to block. The next day, the blocking solution was 
discarded and the appropriate antibody (anti-His monoclonal [Clontech, Moutain View, 
California, USA]/anti-MBP monoclonal [NEB]) was diluted 1:4 in 1X TBS + 1% fish gelatin and 
incubated for 1 hour at room temperature with gentle shaking. The membrane was washed with 
1X TBS for 10 minutes and incubated with secondary goat anti-bovine antibody (KPL) diluted 1:2 
for 1 hour at room temperature with gentle shaking. Once developed with the addition of AP buffer, 
BCIP and NBT, the membrane was washed with ddH2O for 10 minutes and dried on the bench 
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overnight. Transformants that positively expressed Receptor 1372 and Tbp1 were grown 
overnight, diluted 1:1 in 40% glycerol and stored at -80 ⁰C. 
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Table 4-2 Primers used in this study 
Target Gene Product 
Size 
(bps) 
Vector Annealing 
temp (⁰C) 
Strain Enzyme 
Sites 
Sequence E. coli 
strains 
used 
TonB-
dependent 
receptor 
(HSM_1372) 
2388 pGH433His 63 2336 BglII 
NcoI 
Forward: 
5’CACCAGATCTGA
AACAAGTAAAAAT
AAAGTTGAACGAC 
3’ 
Reverse: 
5’CACCCATGGTTA
GAATTCATACCCT
AATTC 3’ 
DH5αFʼIQ 
Transferrin-
binding 
protein 1 
(HSM_0750) 
2916 pGH433His 50, 58 and 
60 (3.5-4 
min 
extension) 
2336 
 
SmaI 
NcoI 
Forward: 
5’CGCGCGCCCGG
GAAAAAAATGTCT
ACAAAACCTTTG 
3’ 
Reverse: 
5’CGCGCGCCATGG
TTAAAACTTCATT
TCCATAC 3’ 
DH5αFʼIQ 
M15 
3073 pAA352 50 (3.5 
min 
extension) 
AVI1 SmaI 
NcoI 
Forward: 
5’GGCGCGCCCGG
GATCTACAAAACC
TTTGTTTAAAC 3’ 
Reverse: 
5’GCTCCGCCATGG
ER2523 
BL21pLys 
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TTAAAACTTCATT
TCCATACTCAC 3’ 
3063 pMAL-c5X 60 (4 min 
extension) 
AVI1 EcoRI 
HindIII 
Forward: 
5’GCGCGCAATTCG
AACTTAAGCCAAT
AACATTG 3’ 
Reverse: 
5’CGCGCGAAGCTT
TTAAAACTTCATT
TCCATACTCACGG 
3’ 
ER2523 
BL21pLys 
Transferrin-
binding 
protein 2 
(HSM_0749) 
1989 pAA352 50 
(3.5 min 
extension) 
2336 NcoI 
BamHI 
Forward: 
5’GGCGCGGGATC
CGGCTTTTCGGTC
TTGAGTG 3’ 
Reverse: 
5’CGCCGGCCATGG
TCATTTCTATTTCG
ATAGTTCTTG 3’ 
M15 
1989 pMAL-c5X 60 (4 min 
extension) 
EcoRI 
HindIII 
Forward: 
5’CGCGCGGAATTC
CGGCTTTTCGGTC
TTGAGTG 3’ 
Reverse: 5’ 
CGCCGGAAGCTTT
CATTTCTATTTCG
ATAGTTCTTG 3’ 
ER2523 
BL21pLys 
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4.3 Protein purification 
The TonB-dependent receptor 1372 was purified using a modified Ni-NTA column protein 
purification method [35]. E. coli DH5αFʼIQ that positively expressed the receptor was used to 
inoculate 10 mL of fresh LB containing 100 μg/mL ampicillin, grown overnight at 37 ⁰C and 
diluted 1:50 in warm 490 mL LB-ampicillin broth. Once the culture reached an OD600 of 0.6, 1 
mL was collected as a non-induced sample. A final concentration of 1 mM IPTG was added to the 
remaining culture and both cultures were grown aerobically at 37 ⁰C for 2-3 hours with shaking at 
200 rpm. Cells were harvested by centrifugation at 6,500 rpm for 20 minutes at 4 ⁰C, resuspended 
in 4 mL of 1X Buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM Imidazole, pH 8.0) and stored 
overnight at -80 ⁰C. The next day, the tube was thawed at room temperature. One mL of 10 mg/mL 
lysozyme was then added to the thawed pellet along with a sterile stir bar and the pellet stirred on 
ice for 30 minutes. The cells were lysed by sonication using Sonics Virba Cell (Betatek Inc. North 
York, Ontario) at 40%, 5 times for 30 s using a ½ inch probe. The lysed cells were centrifugated 
at 10,000 rpm for 30 minutes at 4 ⁰C. The pellet was washed in 1X Buffer with the same 
centrifugation conditions before the final pellet was resuspended in 4 mL 2X Buffer (50 mM 
NaH2PO4, 300 mM NaCl, 20 mM Imidazole, 8 M Urea, pH 8.0) and stirred on ice for 1 hour. The 
supernatant containing protein was obtained following centrifugation at 10,000 rpm for 30 minutes 
at 4 ⁰C and stored at -20 ⁰C. To purify the protein from the supernatant, 1 mL of Ni-NTA resin 
(Qiagen, Hilden, Germany) was added to the 4 mL lysate, left on a Nutator for 1 hour and gently 
loaded onto an empty column (BioRad). Flow-through was collected before the column was 
washed twice with 4 mL of Buffer C (100 mM NaH2PO4, 10 mM Tris Cl, 8 M Urea, pH 6.3) and 
eluted 4 times with 0.5 mL Buffer D (100 mM NaH2PO4, 10 mM Tris Cl, 8 M Urea, pH 5.9). 
Finally, a second elution was carried out using 0.5 mL Buffer E (100 mM NaH2PO4, 10 mM Tris 
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Cl, 8 M Urea, pH 4.5) applied 4 times. All elutions were collected in falcon tubes (VWR) from 
which 10 μL of sample was taken and mixed with 20 μL of 2x sample buffer before being run on 
a 10% SDS-PAGE gel. Densitometry was used to determine the protein concentration found in the 
elutions by comparing the values to those of known BSA standards using the program ImageLab. 
Flow-through fractions that still contained protein were passed through the column a second time.  
Purification of Tbp1 was carried out following the protocol outlined in the pMAL Protein 
Fusion and Purification System (NEB). A glycerol stock of strain BL21pLys expressing Tbp1 was 
used to inoculate 10 mL of Rich Broth (10 g Tryptone, 5 g Yeast Extract, 5 g NaCl, 2 g Glucose) 
that was incubated overnight at 37 ⁰C. The overnight culture was used to inoculate 1 L of Rich 
Broth and grown until an OD600 of 0.6 was reached when the culture was split and one half induced 
with 1 mM IPTG. The induced and non-induced cultures were incubated for 2 hours at 37 ⁰C. 
Once induced, a second sample was taken and the cells were harvested by centrifugation at 4,000 
x g for 20 minutes in 3 sterile centrifuge bottles. The pellets were resuspended in 15 mL of column 
buffer (20 mM Tris-HCL, 200 mM NaCl, 1 mM EDTA) and stored in a falcon tube at -80 ⁰C. The 
next day the thawed sample was sonicated to lyse the cells. The protein-containing supernatant 
was obtained through centrifugation at 20,000 x g for 20 minutes and was subsequently diluted 
1:2 with column buffer. The amylose resin (NEB) was prepared by pouring into columns and 
washing twice with 4 mL column buffer. The lysate was loaded carefully onto the columns and 
the flow-through collected. The columns were then washed 4 times with 9 mL of warm column 
buffer while collecting the first 4 mL as 1 mL fractions. The protein was eluted with 10 mL of 50 
⁰C column buffer containing 10 mM maltose and 1 mL fractions were collected. Elutions were 
also attempted using 50 mM maltose. Because BL21pLyse was not the strain recommended by 
NEB, E. coli ER2523 that expressed Tbp1 was used in a second purification with the addition of 
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protease inhibitor in order to avoid any possible degradation of the fusion protein. The protein was 
eluted using column buffer containing 100 mM maltose followed by the addition of 2 M Urea. 
Elution was also attempted using 4 M Urea and Isopropanol (Sam Attah-poku, VIDO-Intervac).  
As an alternative to the amylose column, anion exchange was used as a pilot experiment 
to determine the purification protocol for the MBP-Tbp1 fusion protein. E. coli ER2523 that 
expressed Tbp1 was used for fresh large-scale inductions as described above. The sonicated 
supernatant from the fresh culture was purified using anion exchange chromatography and the 
protein found in the flow-through fractions. To further process the flow-through, samples were 
pooled together, centrifuged at 13,000 rpm for 15 minutes and both the pellet and supernatant 
individually washed with 2 M Urea, 1 M Guanidine-HCl and 10 mL PBS. The samples were 
centrifuged again and dissolved in 8 M Guanidine-HCl/4 M Urea before being diluted with buffer 
(50 mM PBS, 4 M Urea, 10 mM Maltose, 0.5 mM DOC, 1 mM EDTA, pH 8.0). The samples were 
further purified by size-exclusion chromatography using Superdex 200 prep grade resin and Buffer 
(50 mM PBS, 1 M Guanidine-HCl, 4 M Urea, 10 mM Maltose, 0.25 mM DOC, 1 mM EDTA, pH 
8.0). In continuation of locating the protein, the original pellet was explored further using an 
expanded version of the processing protocol. The sonicated pellet was resuspended in ddH2O and 
large pieces of protein gently broken up with a pipette. The sample was centrifuged at 13,000 rpm 
for 15 minutes before buffer (50 mM PBS, 0.5 mM DOC, 10 mM Maltose, 1 mM EDTA, pH 7.5) 
was added to the pellet and mixed. The pellet was washed with the addition of 2.4 g solid Urea to 
a final concentration of 2 M, 10 mL of 50 mM PBS to dilute the DOC concentration and 2.87 mg 
of solid Guanidine-HCl to a final concentration of 1 M Guanidine-HCl and the solution mixed and 
heated for 1.5-2 hours. The pellet was separated from the supernatant by centrifugation at 13,000 
rpm for 15 minutes and 15 mL of warm 8 M Guanidine-HCl/4 M Urea was added to dissolve the 
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insoluble material. The sample was heated, mixed for 1 hour and the supernatant was separated 
from the pellet by centrifugation at 13,000 rpm for 15 minutes. The supernatant was then diluted 
with buffer (50 mM PBS, 4 M Urea, 10 mM Maltose, 0.5 mM DOC, 1 mM EDTA, pH 8.0) to a 
final buffer concentration of 50 mM PBS, 1 M Guanidine-HCl, 4 M Urea, 10 mM Maltose, 0.5 
mM DOC and 1 mM EDTA. The sample was concentrated using 15 mL x 50 kDa concentrators 
(Millipore). Fractions containing protein were pooled together and further purified by size-
exclusion chromatography as above. The final fractions were pooled based on their relative purity 
on a 7.5% SDS-PAGE gel into 90% and 85% pools and concentrations of each were determined 
by densitometry (ImageLab) using BSA standards as described above. 
Transformants expressing Tbp2 were not obtained when using either of the pAA352 or 
pMAL-c5X vectors. A previous contruct that contained the HS25 tbp2 gene was used to purify 
Tbp2. The strain was streaked from a glycerol stock onto LB agar containing 100 μg/mL ampicillin 
and grown overnight at 37 ⁰C. Ten mL of fresh LB-ampicillin was inoculated with fresh colonies. 
Once grown overnight, the 10 mL culture was added to 990 mL of LB-amp broth and grown until 
an OD600 of 0.6 was reached. A sample of uninduced culture was taken before the remaining 
culture was induced with 1 mM IPTG final concentration and incubated for 2-3 hours after which 
an induced sample was taken. To harvest the cells, the culture was centrifuged at 4,000 x g for 15 
minutes and the pellet resuspended in 4 mL of 25% sucrose and 50 mM Tris (pH 8.0). The 
resuspended pellet was stored overnight at -80 ⁰C. The next day, the pellet was thawed at room 
temperature before 10 mg/mL lysozyme was added and the sample placed on ice for 15 minutes. 
Fresh RIPA/TET (5:4 RIPA [20 mM Tris pH 8.0, 0.3 M NaCl, 2% Deoxycholic acid, 2% IGEPAL 
(NP-40)] TET [0.1 M Tris pH 8.0, 50 mM EDTA, Triton X-100]) was added at a volume of 30 
mL to the lysed pellet. Once mixed and left on ice for 5 minutes, the protein was obtained by 
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sonication at 80% 5 times for 30 s. Once sonicated, the cells were harvested by centrifugation at 
12,000 rpm for 20 minutes at 4 ⁰C. The protein containing pellet was resuspended in 0.5 mL of 
4M Urea and stored at 4 ⁰C or run directly on a 10% SDS-PAGE gel. The concentration of the 
protein was determined with densitometry (Imagelab) by comparing the bands to known BSA 
standards. 
4.4 Immunization and infection of cattle 
Each 2 mL vaccine dose for cattle contained 250 μg of CpG2007, 30% Emulsigen (MVP 
Laboratories Lot# 2700), 100 μg of each protein and was made up to 2 mL with 0.1 M PBSA. 
Mice received a 40 μL dose containing 10 μg of CpG2007, 30% Emulsigen, 10 μg of each protein 
and 0.1 m PBSA. PBSA was the first reagent added followed by the proteins to ensure they 
remained in solution and did not precipitate. Following the protein, CpG2007 was added before 
finally adding the Emulsigen. The vials were sealed, thoroughly mixed, labelled and stored at 4 ⁰C 
for use the next morning. Cattle vaccines were delivered sub-cutaneously while murine 
immunizations were delivered intra-muscularly.  
A previous challenge experiment determined the optimal amount of H. somni AVI1 to be 
108 colony-forming units (CFU)/mL. Calves were only moderately ill when challenged with 108 
and in order to increase the stringency of infection, 7.5 x 108 CFU/mL of Histophilus somni AVI1 
was used for the preliminary trial testing Receptor 1372. When testing Receptor 1372 along with 
Tbp1 and Tbp2, the challenge was 3.75 x 109 CFU/mL. All challenges were administered to the 
calves intravenously following blood sampling. These samples of blood were taken to obtain 
PBMCs and serum at the times of first immunization, boost, challenge, and post-mortem. All 
animals were examined daily and clinical scores, temperatures and weights recorded.  
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This study was randomized, controlled and blind. With the aid of a random numbers 
generator, calves were assigned to treatment groups. All calves were individually identified with 
an ear tag and housed in the same pen throughout the study. Investigators were kept unaware of 
the treatment status of the individual animals until the initiation of the data and statistical analysis. 
4.5 PBMC isolation, spleen processing and cell stimulation 
To determine if TonB-dependent proteins had the capacity to induce both cellular and 
humoral immune responses, a pilot cattle trial was done by immunizing calves with Receptor 1372 
(Figure 4-4). Both the immunized and control groups contained 8 calves each and on day 0, they 
received the first immunization containing 100 μg of Receptor 1372. On day 30, the calves 
received a boost immunization and 2 weeks later on day 44, they received an intravenous challenge 
of H. somni AVI1 at about 109 CFU/mL. One to two weeks later, depending on the clinical 
symptoms, the animals were euthanized for post-mortem sampling. Peripheral blood mononuclear 
cells (PBMCs) were isolated from 100 mL blood samples. Peripheral blood mononuclear cells 
were isolated as described [74]. The buffy coat containing the PBMCs was obtained by 
centrifugation of blood samples at 2,500 rpm for 20 minutes without brake. This buffy coat was 
then mixed with 20 mL PBSA + 2.7 mM Ethylenediaminetetraacetic acid (EDTA) before being 
gently layered on 12 mL of Ficoll (GE Healthcare, Mississauga, Ontario, Canada), topped up to 
50 mL with PBSA + EDTA and centrifuged at 3,000 rpm for 20 minutes without brake. The buffy 
coat was again mixed with 20 mL PBSA/ 2.7 mM EDTA and topped up to 50 mL. Washing 
PBMCs consisted of centrifugation at 1,200 rpm for 10 minutes, discarding the supernatant and 
gently resuspending cells by knocking the tubes together before filling them with 50 mL PBSA. 
This was repeated 3 times before cells were resupended in 5 mL of PBSA. Cells were counted by 
diluting 1:100 in PBSA and using a Sceptre cytometer (Milipore, Billerica, Massachusetts, USA) 
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with 40 μm sensors (Millipore) or a hemocytometer with a 1:2 dilution of cells in Turk’s 
(Millipore) solution. PBMCs were used in proliferation assays as discussed in section 4.6.  
A second cattle trial took place to characterize the immune responses and protective 
capacity when immunized with Receptor 1372, Tbp1 and Tbp2. The animal trial was designed 
similarly to the above mentioned cattle trial with animals receiving 100 μg each of Receptor 1372, 
Tbp1 and Tbp2. Blood was sampled on days 0, 30, 44 and 50, and PBMC isolation followed the 
same protocol as described above.  
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Figure 4-4 Cattle trial protocol. Cattle were split into 2 groups: vaccine and control, each 
consisting of 8 animals. Animals were immunized on Day 0 and day 30. The intra-venous 
challenge of H. somni AVI1 was given on Day 44. Post-mortem followed 1-2 weeks after 
challenge. Samples of blood were taken at each time point for PBMC isolation.  
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A murine trial determined if receptor 1372, Tbp1 and/or Tbp2 were capable of inducing a 
cellular response in mice (Figure 4-5). In this trial, all mice were randomly assigned to both group 
and cage. On day 0, 2 groups of five mice were immunized with 10 μg each of Receptor 1372, 
Tbp1 and Tbp2. On this same day one group of five control mice was sacrificed and their spleens 
removed for processing following an adapted spleen processing method from Benencia et al. [75]. 
On day 14, five of the immunized mice received a second immunization while the remaining five, 
along with five controls, were euthanized and spleens processed. On day 28, all remaining animals 
were euthanized and splenocytes isolated. Spleens were immediately placed in 15 mL Minimal 
Essential Media (MEM) (Sigma-Aldrich) + 10 mM HEPES (Lifetech, ThermoFisher Scientific, 
Waltham, Massachusetts, USA), 50 U/mL Penicillin/Streptomycin (Gibco, ThermoFisher) and 
kept on ice. To isolate splenocytes, a spleen was placed in a sterile petri dish with 5 mL MEM and 
a 40 μm strainer (ThermoFisher). Once moved to the strainer, the spleen was cut into pieces with 
sterile scissors and gently pushed through using a sterile glass plunger until there was little to no 
spleen left. The strainer was rinsed multiple times with the 5 mL of MEM before being moved to 
a 15 mL falcon tube. The petri dish was also washed to remove all cells. Cells were centrifuged at 
311 x g for 10 minutes at 4 ⁰C, media poured off or carefully removed with a pipette and the pellet 
resuspended by knocking tubes together and adding 5 mL of AIM V (Gibco, ThermoFisher) + 50 
U/mL Penicillin/Streptomycin, 0.1 μM β-mercaptoethanol, 10% Fetal bovine serum (FBS) (Gibco, 
ThermoFisher). Cells were counted using the hemocytometer by diluting 1:4 in PBSA and 1:2 in 
Turk’s solution. Isolated splenocytes were re-stimulated with each protein for RNA isolation (see 
section 4.7). Once counted, cells were diluted or concentrated to 1 x 106 cells/well and allowed to 
stabilize for 1 hour at 37 ⁰C with 5% CO2 while each protein was diluted to 1 ng and 10 ng. 
Concanavalin A (ConA) (Sigma-Aldrich) was diluted to 2 μg/mL. Once stabilized, 100 μL of cells, 
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in triplicate, were incubated at 37 ⁰C with 5% CO2 for 20 hours with 100 μL of each antigen. ConA 
was used as a positive control and media for a negative control.   
This study was randomized, controlled and blind. With the aid of a random numbers 
generator and a computer spreadsheet (Microsoft Excel), mice were randomly assigned to both 
cage and treatment groups. Equal numbers of mice from each treatment group were housed in each 
cage and within each cage; mice were individually identified with randomly assigned ear notches. 
Investigators were kept unaware of the treatment status of the individually animals until the 
initiation of data and statistical analyses. 
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Figure 4-5 Murine trial protocol. Mice were split into 5 groups: 3 control groups, 1 vaccine 
group and 1 boost group. On day 0, a control group was sacrificed as a negative control, while the 
vaccine and boost groups were immunized. On day 14, the vaccine group and a second control 
group was sacrificed while the boost group received a second immunization. On day 28, the boost 
group and remaining control group were sacrificed. Spleens were removed from all sacrificed 
animals and processed to isolate the splenocytes for qPCR analysis. 
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4.6 CFSE staining and proliferation assays 
For both cattle trials, isolated PBMCs were stained for proliferation assays following the 
CFSE staining method [76]. Carboxyfluorescein succinimidyl ester (CFSE) (Life Technologies) 
was spun down, reconstituted with 18 μL of Dimethyl Sulfoxide (DMSO) (Sigma-Aldrich) for a 
final concentration of 5 mM and centrifuged briefly again. PBMCs were diluted or concentrated 
to 2 x 107 cells/mL in PBSA and allowed to adjust to room temperature. CFSE was diluted to a 
working concentration of 5 μM, 1 mL added to each cell suspension, mixed rapidly and incubated 
in a 37 ⁰C water bath for 10 minutes. The reaction was immediately stopped by the addition of 2 
mL FBS and gentle inversion to mix thoroughly. Cells were incubated at room temperature in the 
dark for 15 minutes after which cells were harvested by centrifugation at 400 x g for 8 minutes. 
PBMCs were washed thoroughly twice by resuspension in 14 mL room temperature MEM 
complete (MEM + 0.05 mg/mL Gentamycin sulphate [Bio Basic], 10% FBS, 50 μM β-
mercaptoethanol, 5 mL sodium pyruvate [Lifetech, ThermoFisher], 5 mL Non-essential amino 
acids [NEAA] [Lifetech, TermoFisher], 5 mL HEPES) and centrifuged at 400 x g for 8 minutes. 
Supernatants were discarded while cells were resuspended in 14 mL MEM complete and incubated 
at 37 ⁰C plus 5% CO2 for 30 minutes. Once incubated, PBMCs were harvested by centrifugation 
at 350 x g for 8 minutes, resupended in 5 mL MEM complete and diluted 1:10 in PBSA for 
counting with either the Scepter or hemocytometer as mentioned above.  
PBMCs, stained with CFSE, were set up for proliferation assays using receptor 1372, Tbp1 
and Tbp1 to stimulate the cells. Cells were diluted to a final amount of 1 x 106 cells/mL and 100 
μL plated with each treatment. The treatments for the pilot experiment consisted of: 1 ng, 2 ng, 10 
ng, 20 ng and 30 ng of receptor 1372, 2 μg/mL ConA and media to determine the ideal 
concentration of protein for re-stimulation. For the final cattle trial, the PBMCs were treated with 
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20 ng of each protein, 2 μg/mL ConA and media. Cells were incubated with the treatments at 37 
⁰C plus 5% CO2 for 4 days. On day 4 of incubation, proliferation was measured by BD 
FACSCalibur (Bio-Rad Laboratories) and CellQuestPro. Analysis was done by using the programs 
Kaluza and Graphpad Prism with the gating strategy shown in Figure 4-6. 
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Figure 4-6 PBMC gating strategy. Proliferation of PBMCs was measured using flow-cytometry. 
The gating strategy consisted of gating the PBMCs using gate A, where cells were measured by 
the side-scatter (SSC-H) and forward-scatter (FSC-H). This was followed by gating of the 
proliferating cells (gate C) from the total population (gate B). Here, cells were graphed using 
forward-scatter and the amount of CFSE fluorescence. The histogram shows the number of 
proliferating PBMCs (Count) by quantity of intracellular CFSE. 
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4.7 Gene expression analysis by qPCR 
Analysis of gene expression through Quantitative PCR (qPCR) began with isolation of 
RNA from re-stilumated murine splenocytes using an RNeasy isolation kit (Qiagen). Stimulated 
splenocytes were pooled into Eppendorf tubes and harvested by centrifugation at 400 x g for 15 
minutes at 4 ⁰C before being lysed with 400 μL of lysis buffer (RLT). The samples were then 
vortexed for 1 minute each and frozen at -80 ⁰C until isolation. For isolation, the lysed cells were 
thawed on ice and 1 volume of 70% ethanol added, mixed and 700 μL transferred to a column 
placed in a 2 mL collection tube. Columns were centrifuged at 8,000 x g for 30 s after which the 
flow-through was discarded and 700 μL of Buffer RW1 added before centrifugation at 8,000 x g 
for another 30 s. The flow-through was discarded and column washed with Buffer RPE and 
centrifuged again. Another 500 μL of RPE was added to the column, which was centrifuged at 
8,000 x g for 2 min. At this point, it was imperative to keep the workspace and pipettes RNase-
free. The column was placed into a new 1.5 mL collection tube, 30 μL of RNase-free water (Sigma-
Aldrich) was added and the column was left to sit for 1-2 minutes before centrifugation at 8,000 x 
g for 1 min to elute the RNA. The elution step was repeated using the 30 μL of eluate from the 
previous step. Concentration and purity of the RNA was determined using the Nanodrop ND-1000 
Spectrophotometer (ThermoFisher) before being reverse transcribed using the High-Capacity 
Reverse Transcription kit (Applied Biosciences, Foster City, California, USA). Each RNA sample 
was diluted to 500 ng with the RNase-free water (Sigma-Aldrich) while also including plate 
controls. A mastermix was made with 10X RT Buffer, 25X dNTO mix (100 nm), 10X RT random 
primers and MultiScribe reverse transcriptase according to the kit manual. Mastermix was added 
to the samples at a volume of 5.8 μL. The reactions were run on a PTC-100 Thermal Cycler (Bio-
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Rad) with the following steps: step 1 at 25 ⁰C for 10 min, step 2 at 37 ⁰C for 120 min and step 3 
at 85 ⁰C for 5 min. All cDNA was stored at -20 ⁰C until set-up for qPCR reactions. 
Gene expression was measured from the splenocyte cDNA using the qPCR method [77]. 
The cDNA was diluted to 100 μL with RNase-free water. A mastermix was created using Kapa 
Sybr Fast qPCR Mastermix ABI Prism (Kapa Biosystems, Wilmington, Massachusetts, USA), 
forward and reverse primers specific for Interleukin-4 (IL-4), Interferon-gamma (IFNγ) or 
Ribosomal protein L19 (RPL19) (Table 4-6) and RNase-free water. Two μL of cDNA was added 
to qPCR plates (Applied Biosystems) and 13 μL of the above mastermix. Plate covers (Applied 
Biosystems) sealed the plates, which were centrifuged briefly and stored overnight at -20 ⁰C. The 
next day, plates were thawed at room temperature in the dark, centrifuged briefly and checked for 
air bubbles before being set up on StepOnePlus Real-Time PCR Systems (Applied Biosystems). 
Once set-up each plate was measured for the expression of IL-4 or IFNγ. Analysis was carried out 
using Microsoft Excel and Graphpad Prism.  
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Table 4-3 qPCR primers 
Gene target Primer name Tm (⁰C) Sequence 
IL-4 IL4 Forward 60.17 GAGAGATCATCGGCATTTTGA 
IL4 Reverse 59.88 GGTGTTCTTCGTTGCTGTGA 
IFNγ IFNg Forward 60.3 CACGGCACAGTCATTGAAAG 
IFNg Reverse 59.3 TCATGTCACCATCCTTTTGC 
RPL19 (control) RPL19 Forward 59.31 CCTCATGCCCACAAGGTACT 
RPL19 Reverse 59.99 CCCTGTCTTGTATCGCTCCT 
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4.8 ELISA assays  
Serum titres for all cattle trials were measured with enzyme-linked immunosorbent assays 
(ELISAs) adapted from the ELISA method described by Darshud et al [78]. Immulon 2 96U plates 
(ThermoFisher) were coated with 10 ng of each receptor 1372, Tbp1 and Tbp2 per well using 
Coating buffer (15 mM sodium carbonate, 35 mM sodium bicarbonate) before being left overnight 
at 4 ⁰C. The next day the plates were washed 6 times with tap reverse osmosis (RO) water, wells 
blocked with the addition of 100 µL 1X TBST + 0.5% fish gelatin (Sigma-Aldrich) and left at 
room temperature for 1 hour. While blocking the plates, cattle serum and control serum was diluted 
1/40 and serially diluted 2-fold down a 96 well plate using 1X TBS. Once plates were blocked, 
they were washed again with tap RO water, the diluted serum moved to the blocked plate and left 
at room temperature for 2 hours. Plates were washed again before goat anti-bovine alkaline 
phosphatase (AP) conjugated secondary antibody diluted 1/2000 in 1X TBST was added to each 
well before being left at room temperature for 2 hours. Once plates were washed to remove 
secondary antibody, a 0.1 g/mL stock of P-Nitrophenyl Phosphate (PNPP) was diluted to 1 mg/mL 
in Substrate buffer (0.5 mM MgCl2, 10 mL Diethanolamine) and added to the plates that were then 
left to develop in the dark at room temperature for up to 1 hour. Plates were checked every 10 
minutes to ensure plates did not over-develop. Optical densities were measured using an iMark 
Microplate Reader (Bio-Rad) set to 405 nm. Serum titres were determined using Microsoft Excel 
through determination of the cutoff (average of negatives + 2 standard deviations). Using this 
cutoff value enabled the determination of titres based on the forecast formula.  
The expression of IL-4 and IFNγ was confirmed with the use of cytokine ELISAs following 
the Duo-set ELISA Development System kit protocol (R & D Systems, Minneapolis, Minnesota, 
USA). In the event that IL-4 assays did not work, Interleukin-5 (IL5) was also used to confirm the 
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humoral response seen through qPCR. The capture antibody was diluted to 4.0 μg/mL in PBS and 
used to coat Immulon 2 96U plates overnight at room temperature. The next day, plates were 
washed 3 times with washing buffer (0.05% Tween 20 in PBS, pH 7.2 - 7.4) and blocked with 
appropriate blocking buffer (specific for each cytokine: 0.1-1% BSA in PBS) at room temperature 
for 1 hour. The plates were washed again and supernatant from stimulated murine splenocytes 
diluted 1:10 in Reagent diluent (specific for each cytokine: 0.1-1% BSA, 0.05% Tween 20 in TBS, 
pH 7.2 - 7.4) along with Standard (diluted to 2 ng/mL), in duplicate, and incubated at room 
temperature for 2 hours. Once plates were washed, detection antibody specific for the cytokine 
was diluted to 800 ng/mL in reagent diluent, added to the plates and left at room temperature for 
another 2 hours. After washing again, Strepdavidin-HRP (R & D Systems) was diluted in reagent 
diluent to working concentration on the bottle. These were then added to each well and left to 
develop at room temperature for 20 minutes in the dark. Again, the plates were washed and 100 
μL of SureBlue TMB microwell peroxidase substrate (KPL) was added directly to each well and 
plates left for another 20 minutes in the dark. After development, 50 μL of Stop Solution (2 N 
H2SO4) was added to each well before the plates were read with a  SpectraMax Plus microplate 
reader (Molecular Devices, Sunnyville, California, USA) set to 450 nm. Analysis was done using 
Microsoft Excel and Graphpad Prism.  
4.9 Statistical analyses 
All statistical analysis of serum ELISA used non-parametric t-test (Mann-Whitney) and 
qPCR results used two-way ANOVA with Sidak’s multiple comparison test. Statistical analysis of 
cytokine ELISA used unpaired t-test t compare non-immunized and immunized groups. Statistics 
for proliferation assays used parametric t-tests in order to compare the immunized and non-
immunized groups. All statistical analyses were completed using Graphpad Prism software. 
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Significant results were determined by P value where a P value greater than 0.05 is not significant 
and less than or equal to 0.05 is significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
61 
 
5.0 RESULTS 
5.1 Gene cloning and purification of Receptor 1372  
In order to obtain purified Receptor 1372 for use in animal trials, the gene coding for the 
receptor was amplified using PCR and the vector pGH433His was used for ligation. Following 
ligation, E. coli DH5αFʼIQ were transformed. Transformants were screened using the colony PCR 
method previously described followed by further screening to identify clones expressing the 
protein. Once transformants were expressing the Receptor 1372, lysed cells were passed through 
a Ni-NTA column that binds the His6-tagged protein. The use of SDS-PAGE identified elutions 
containing Receptor 1372 and the use of densitometry determined the concentrations.  
Receptor 1372 was amplified from genomic H. somni AVI1 DNA, ligated, transformed 
and expressed. Once expressed, the protein was purified. Amplification of the receptor 1372 using 
the primers specified for pGH433His resulted in DNA bands of 2388 base pairs (bp) (Figure 5-
1A). The ligated insert DNA was transformed into E. coli DH5αFʼIQ and the transformants 
screened for the expression of Receptor 1372 using small-scale IPTG induction (Figure 5-1B). The 
protein was expressed at a size of 90 kD, as expected, by 2 transformants (1372_#4 and 1372_#9). 
Western blotting using an antibody specific for the His6-tag of the protein confirmed the expression 
of Receptor 1372 (Figure 5-1C). Confirmed transformants were used to inoculate large-scale 
cultures in order to produce large amounts of protein. The protein was purified by passage through 
a Ni-NTA column that resulted in the protein being eluted in fractions 1-5 (Figure 5-2). Often the 
protein was also found in the flow-through due to the resin becoming saturated so it was passed 
through the column a second time. Thus, the gene coding for Receptor 1372 was cloned using the 
in-house vector pGH433His, expressed in E. coli DH5αFʼIQ and the protein purified using Ni-
NTA columns. 
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Figure 5-1 PCR and small-scale IPTG induction of Receptor 1372. (A) Amplification of 
receptor 1372 from the H. somni strain AVI1 using primers designed for ligation with vector 
pGH433His. (B) SDS-PAGE gel of small-scale induction where 2 clones (1372_#4 and 1372_#9) 
are expressing Receptor 1372 when induced with IPTG (addition of IPTG indicated by ‘+’). (C) 
Small-scale induction samples were transferred to nitrocellulose for western blot using anti-His6 
monoclonal antibody to confirm Receptor 1372 protein expression. 
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Figure 5-2 SDS-PAGE gel of purified Receptor 1372. Fractions 1 through 5 containing purified 
Receptor 1372. Densitometry used BSA standards to determine the concentration of protein in 
each elution. Elution 1 (0.3 μg/μL), Elution 2 (0.4 μg/μL), Elution 3 (0.04 μg/μL), Elution 4 (0.12 
μg/μL), Elution 5 (0.36 μg/μL). 
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5.2 Gene cloning and purification of Transferrin-binding protein 1 (Tbp1)  
In order to acquire purified Tbp1 for use in animal trials, tbp1 was amplified and the DNA 
used for ligation with vectors pGH433His and pAA352. When these were unsuccessful, newly 
amplified DNA was ligated into the vector pMAL-c5X. Once ligated into pMAL-c5X, E. coli 
ER2523 and BL21pLys cells were transformed and then screened by colony blotting. Further 
screening identified transformants containing the gene of interest as expressing Tbp1. Once 
expression of Tbp1 was obtained, the protein was purified through various attempts including 
amylose columns that were unsuccessful. Affinity chromatography led to the development of a 
processing protocol that identified Tbp1 in flow-through and pellet samples. These samples were 
further purified by size-exclusion chromatography in order to obtain pools of purified Tbp1.  
The cloning and purification of Tbp1 was important to obtain two pools of known 
concentration, 90% and 80%, used in the immunization of cattle and mice. The gene coding for 
Tbp1 was amplified using primers designed specifically for cloning into the vectors pGH433His 
and pAA352 (results not shown). These PCR fragments were then used for ligation and 
transformation into E. coli DH5αFʼIQ and M15. However, the transformants that were isolated did 
not contain the insert gene so tbp1 was amplified using primers specific for pMAL-c5X that 
resulted in DNA bands of about 3000 bp (Figure 5-3A). This DNA was used for ligation in pMAL-
c5X and transformation into E. coli ER2523 and BL21pLys. Transformants were screened for 
Tbp1 expression immediately by colony blotting due to the large number of clones. This resulted 
in the identification of two transformants shown in Figure 5-3B. These two transformants were 
further screened by small-scale IPTG induction and both showed expression of the MBP-Tbp1 
fusion protein at the expected size of 160 kD (Figure 5-3C). Western blot using anti-MBP antibody 
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that bound the MBP portion of the fusion protein confirmed protein expression (Figure 5-3D). 
Both transformants, along with 4 others had positive expression of Tbp1. 
In order to produce larger quantities of the fusion protein, strain BL21pLys_Tbp1_1 was 
grown in 3 litres and the protein harvested as described for purification on amylose resin. The 
MBP binds strongly to the amylose resin but has a stronger affinity for the maltose used to elute 
the protein. This, however, did not appear to be the case and it was found that MBP-Tbp1 would 
bind to the resin and not elute regardless of the concentration of maltose used. Since the strain 
BL21pLys was not the strain suggested by NEB, the clone ER2513_Tbp1_2 was used for a second 
attempt. Protease inhibitor was added to this induction to avoid any degradation of the protein 
while the column was eluted with 100 mM maltose. Unfortunately, this, as well as elution with 4 
M Urea and isopropanol did not yield results. A new culture of ER2523_Tbp1_2 was induced and 
harvested as described above to obtain the supernatant that was explored first through affinity 
chromatography. This led to the discovery that the fusion protein was in the flow-through (Figure 
5-4A) while all the contaminants were binding to the column. Through some explorations of the 
sonicated pellet it was discovered that the fusion protein was there as well (Figure 5-4A). Once 
the processing protocol was developed through the analysis of supernatant and flow-through 
samples, it was applied to the flow-through fractions that were then further purified by size-
exclusion chromatography (Figure 5-4B). From here, the sonicated pellet was processed in the 
same way and the results showed that the pellet contained much more fusion protein than the 
supernatant (Figure 5-4C). Using the processed pellet and flow-through samples, two pools of 
MBP-Tbp1 were made: 90% and 80% (Figure 5-4D). Thus, the gene coding for Tbp1 was cloned 
using the maltose fusion vector pMAL-c5X, expressed in E. coli ER2523 and purified using both 
anion exchange and size-exclusion chromatography. 
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Figure 5-3 PCR, colony blot and small-scale IPTG induction of Tbp1. Amplification of Tbp1 
from the H. somni strain AVI1 using primers designed for ligation with vector pMAL-c5X. (B) 
Colony blot after transformation with pMAL-c5X/Tbp1 ligation. Colonies expressing the MBP-
Tbp1 fusion protein are indicated. (C) Small-scale IPTG induction of clones ER2523_Tbp1_1 and 
ER2523_Tbp1_2 where each shows expression of Tbp1. (D) Induced samples of ER2523_Tbp1_1 
and ER2523_Tbp1_2 transferred to nitrocellulose for western blot to confirm protein expression 
with anti-MBP monoclonal antibody. IPTG induction is indicated by ‘+’. 
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Figure 5-4 SDS-PAGE gels of purified Tbp1. (A) Western blot using anti-MBP monoclonal 
antibody showing crude processed pellet, original sonicated pellet, a MBP control, and flow-
through fractions 4-8. The MBP-Tbp1 fusion protein was found in sonicated sample, sonicated 
pellet as well as in the flow-through from anion-exchange of sonicated supernatant. (B) SDS-
PAGE gel of crude pellet and fractions 21-27 showing processed sonicated supernatant with some 
presence of the fusion protein. (C) SDS-PAGE gel of crude pellet and fractions 21-34 showing 
processed sonicated pellet with increased presence of purified MBP-Tbp1. (D) SDS-PAGE gel of 
purified fusion protein from processed sonicated pellet after size-exclusion chromatography. 
Fractions were pooled based on relative purity on SDS-PAGE into 90% and 80%. Processed pellet 
was also found to be quite pure. Densitometry used BSA standards to determine the concentration 
of protein in each aggregate preparation. Nintey % (0.7 μg/μL), 80% (2.8 μg/μL) 
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5.3 Gene cloning and purification of Transferrin-binding protein 2 (Tbp2)  
In order to obtain purified Tbp2, many attempts at cloning were made including the 
amplification and subsequent ligation of tbp2 into vector pAA352. Since this ligation resulted in 
E. coli M15 transformants expressing a smaller protein, the gene was ligated into pMAL-c5X. 
When the gene of interest was not found in these transformants, a decades-old construct, 
HS25_Tbp2, was used for the purification of Tbp2.  
The cloning and purification of Tbp2 began with the use of a leukotoxin fusion vector, 
PAA352. The gene for tbp2 was amplified using primers designed for cloning into pAA352 and a 
band of 1989 bp was found as expected (Figure 5-5A). The DNA was ligated into pAA352 to 
produce a leukotoxin fusion that was transformed into E. coli M15. Transformants were screened 
by colony blotting (results not shown) and potential positives were further screened by small-scale 
IPTG induction (Figure 5-5B). The results showed one transformant expressing a protein, however 
the protein was 90 kD and the fusion of leukotoxin and Tbp2 should yield a protein of about 180 
kD. Amplification of tbp2 with primers designed specifically for pMAL-c5X also resulted in bands 
of approximately 1989 bp (Figure 5-5C). This new insert DNA was ligated into pMAL-c5X and 
the ligation transformed into E. coli ER2523 and BL21pLys. The transformants were screened 
using colony blots (results not shown) and any possible positives were further screened using IPTG 
induction (Figure 5-5D) which yielded no positive results.  
Transformants containing insert DNA for tbp2 were not successful using either pAA352 
or pMAL-c5X; therefore, it was decided that in order to include Tbp2 in future animal trials, it 
was necessary to purify it from a previous construct. Decades ago, tbp2 from strain HS25 was 
cloned into pGH433 and this was saved as a glycerol stock. The homology between AVI1 Tbp2 
and HS25 Tbp2 could not be determined due to the incomplete sequence of AVI1. However, it 
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was previously determined that AVI1 was between the old isolates, including HS25, and the new 
isolates. AVI1 belongs to neither group and therefore it can be assumed that it is the closest to 
HS25 of the new isolates. Transferrin-binding protein 2 was purified using this construct 
HS25_Tbp2 or inclusion bodies, which resulted in large amounts of purified Tbp2 (Figure 5-6). 
Thus, the gene coding for Tbp2 was unable to be cloned using either maltose fusion or leukotoxin 
fusion methods. Therefore, it was purified from an existing construct by aggregate preparations.  
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Figure 5-5 PCR and small-scale IPTG induction of Tbp2. (A) Amplification of Tbp2 from the 
H. somni strain AVI1 using primers designed for ligation with vector pAA352. (B) Small-scale 
IPTG induction of colonies 1 through 6 that were transformed with pAA352/Tbp2 ligation. One 
tranformant showed expression of an incorrectly sized protein (87 kD). Induced cultures indicated 
with ‘+’. (C) Amplification of Tbp2 from the H. somni strain AVI1 using primers designed for 
ligation with vector pMAL-c5X. (D) Small-scale IPTG induction of clones 1-3 transformed with 
pMAL-c5X/Tbp2 ligation. No protein expression was induced. Induced cultures indicated with 
‘+’. 
71 
 
 
 
 
 
 
 
 
 
Figure 5-6 SDS-PAGE gel of purified Tbp2. SDS-PAGE gel of aggregates 1 and 2 containing 
purified Tbp2. Densitometry used serially diluted BSA standards to determine the concentration 
of protein in each aggregate preparation. 
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5.4 Receptor 1372 induces both humoral and cellular immune responses in cattle 
5.4.1 Proliferation responses following immunization with Receptor 1372 
In order to determine the immune responses induced by receptor 1372, the proliferative 
response of isolated bovine PBMCs was analyzed. Samples of blood were taken from each calf 
and PBMCs isolated as previously described. Isolated PBMCs were stained and stimulated with 
Receptor 1372 in order to measure the proliferative response by flow cytometry.   
In order to determine if Receptor 1372 induced a cellular immune response, a group of 16 
calves containing 8 vaccinates and 8 controls, were immunized with 100 μg of purified Receptor 
1372. On day 0, no significant difference between immunized and non-immunized calves was 
observed. This was as expected given that none of the animals had been exposed to the vaccine or 
challenge. Figure 5-7B shows that the proliferation of PBMCs isolated before challenge was 
significantly increased when animals were immunized with Receptor 1372. The PBMCs which 
were stimulated with only 1 ng and 2 ng of receptor 1372 showed no significant increase while the 
cells stimulated with 10, 20 and 30 ng did. These results showed a treatment effect when the 
concentration of antigen was increased for each re-stimulation while also showing that a 10, 20 or 
30 ng treatment was sufficient for re-stimulation. Figure 5-7C shows the results of PBMCs isolated 
2 weeks post-challenge where no significant differences were observed between immunized and 
non-immunized animals. From these proliferation assays, it was possible to conclude that the 
Receptor 1372 was inducing a strong cellular immune response, which also showed a treatment 
effect. 
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Figure 5-7 Proliferation of PBMCs from calves immunized with Receptor 1372. Calves were 
immunized with Receptor 1372 and PBMCs were isolated on Day 0, Day 44 and Day 58. (A) Day 
0 PBMC proliferation before immunization. (B) Day 44 (Pre-Challenge) PBMC proliferation 2 
weeks after calves received a boost immunization. (C) Day 58 (Post-Challenge) PBMC 
proliferation 2 weeks after calves received an intravenous challenge of H. somni AVI1. 
Significance between non-immunized and immunized were determined by parametric t-test 
(*=P<0.05, **=P≤0.01, ***=P≤0.001). 
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5.4.2 Humoral responses following immunization with Receptor 1372 
In order to determine if Receptor 1372 induces a humoral response in immunized calves 
the antibody titres were analyzed by serum ELISA. Blood samples were taken from each calf in 
order to isolate the serum, which was tested for the presence of antibodies specific for Receptor 
1372. The optical densities (ODs) obtained from ELISA were used to determine serum titres 
against Receptor 1372 in each animal, and these are shown in Figure 5-8. The antibody titres to 
Receptor 1372 were significantly increased once the immunized animals received both the first 
immunization and the boost. The titres of Day 44 (Pre-challenge) and day 58 (Post-challenge) were 
significantly higher in the animals immunized compared to the non-immunized animals. These 
results show that Receptor 1372 induces a humoral immune response in cattle. Along with the 
proliferation assays, the serum titres also show that the receptor is immunogenic. 
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Figure 5-8 Serum titres from calves immunized with Receptor 1372. Calves were immunized 
with Receptor 1372 and serum samples taken from both immunized and non-immunized animals 
on Day 0, Boost (day 30), Pre-Challenge (day 44) and Post-Challenge (day 58). Significance 
between non-immunized and immunized were determined by Mann-Whitney test (*=P<0.05, 
**=P≤0.01, ***=P≤0.001). 
76 
 
5.5 Tbp2 induces an increase in IFNγ production in mice 
5.5.1 Quantitative-PCR of IFNγ and IL-4 levels in murine splenocyte RNA 
In order to determine if Receptor 1372, Tbp1 and/or Tbp2 induces an increase in the 
humoral or cellular immune response in mice, splenocytes were isolated from mice that were 
immunized with Receptor 1372, Tbp1 and Tbp2. Once isolated, the splenocytes were stimulated 
with each protein individually before RNA was isolated. With isolated murine RNA, the cellular 
response was analyzed by expression of IFNγ and the humoral response by expression of IL-4. 
Expression of these cytokines was analyzed by qPCR. The results of qPCR as seen in Figure 5-9A 
showed that expression of IL-4 did not change significantly once mice were immunized with the 
receptor 1372, Tbp1 and Tbp2. While there was no significant increase in IL-4 production, there 
was down-regulation of IL-4 when ConA was present. As seen in Figure 5-9B, there was no 
significant increase in production of IFNγ until the last day when animals had received a boost 
vaccination containing receptor 1372, Tbp1 and Tbp2. On day 28, production of IFNγ increased 
significantly in the presence of Tbp2. The results of qPCR showed that Tbp2 was inducing an 
increase in the production of IFNγ and therefore inducing the cellular immune response. There 
was no detectable change in the humoral response through analysis of IL-4.  
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Figure 5-9 Quantitative PCR of IL-4 and IFNγ expression from murine splenocyte RNA. 
Mice were immunized with receptor 1372, Tbp1 and Tbp2. Splenocytes from immunized and non-
immunized mice were isolated and stimulated on day 0, day 14 and day 28. Quantitative PCR 
measured the fold change (2-ΔΔCT) of IL-4 and IFNγ expression at each time point. (A) Expression 
of IL-4 showing the effect of immunization on the humoral response for day 0, day 14 and day 28. 
(B) Expression of IFNγ showing the effect of immunization on the cellular immune response for 
day 0, day 14 and day 28. Significance between non-immunized and immunized were determined 
by two-way ANOVA with Sidak’s multiple comparison test (*=P<0.05, **=P≤0.01, 
***=P≤0.001). 
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5.5.2 Expression of cytokines IFNγ and IL-4 confirmed by ELISA  
In order to confirm the results of qPCR discussed above, cytokine ELISA analyzed the 
presence of both IFNγ and IL-4. When stimulating splenocytes with Receptor 1372, Tbp1 and 
Tbp2, the cells produced cytokines that were released into the media or supernatant. This 
supernatant was used for ELISAs that detect the presence of various cytokines. Both IFNγ and IL-
4 were observed however, the IL-4 results were inconclusive. In order to evaluate the humoral 
response, IL-5, another cytokine involved in the Th1 response was analyzed. The results of 
cytokine ELISA (Figure 5-10) were used to confirm the qPCR results previously discussed. The 
amount of IFNγ expressed by re-stimulated splenocytes increased in the presence of Tbp2 (Figure 
5-10) which was also seen in the results of qPCR. The amount of IL-4 did not change in the animals 
vaccinated (data not shown) so in order to analyze the humoral response, the amount of IL-5 was 
analyzed instead for both vaccinated and control animals (data not shown). The results of cytokine 
ELISAs showed that the amount of IL-5, i.e. the humoral response, remained unchanged between 
both groups while the amount of IFNγ did increase in the presence of Tbp2. These results, along 
with the results of qPCR, show Tbp2 as the only protein of the three capable of inducing an 
increasein the level of IFNγ production. 
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Figure 5-10 Cytokine ELISA of IL-4 and IFNγ expression from murine stimulated splenocyte 
supernatant. Mice were immunized with receptor 1372, Tbp1 and Tbp2. Splenocytes from 
immunized and non-immunized mice were isolated and stimulated for 20 hours with 1 and 10 ng 
treatments each of Receptor 1372, Tbp1 and Tbp2. Analysis of cytokines IL-4 (data not shown), 
IL-5 (data not shown) and IFNγ for Day 28 supernatant from murine splenocytes confirmed results 
of qPCR. Results of IFNγ assay of vaccinated and control animals. Significance between non-
immunized and immunized were determined by unpaired t-test (*=P<0.05, **=P≤0.01, 
***=P≤0.001). 
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5.6 Receptor 1372, Tbp1 and Tbp2 induce both humoral and cellular immune 
responses in cattle 
5.6.1 Proliferation responses following immunization with Receptor 1372, Tbp1 and 
Tbp2 
In order to determine the immune responses induced by receptor 1372, Tbp1 and Tbp2, I 
analyzed the proliferative response of isolated bovine PBMCs by applying the same techniques as 
the previous proliferation assays. It was expected that on day 0, PBMCs would not show a 
significant increase in proliferative response to receptor 1372, Tbp1 and Tbp2 however, Figure 5-
11A showed that there was a significant difference between immunized and non-immunized 
animals for PBMCs stimulated with media, Receptor 1372, Tbp1 and Tbp2. As seen in Figure 5-
11B, the PBMCs that were isolated on the day of boost showed an increase in proliferation only 
with media and Tbp1. On day 44 (Figure 5-11C), PBMCs stimulated with Tbp1 and Tbp2 showed 
a significant proliferative response as expected. It was also expected that Receptor 1372 would 
result in an increase in proliferation but this was not the case. In Figure 5-11D, it was observed 
that none of the treatments resulted in a significant increase in proliferation when animals were 
immunized. These results showed that Receptor 1372, Tbp1 and Tbp2 induced an increase in the 
cellular immune response by causing an increase in PBMC proliferation, which means these 
proteins are immunogenic. However, it is difficult to say that these results are biologically 
significant since the trend is not obvious.  
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Figure 5-11 Proliferation of PBMCs from calves immunized with Receptor 1372, Tbp1 and 
Tbp2. Calves were immunized with Receptor 1372, Tbp1 and Tbp2. PBMCs were isolated on Day 
0, Day 44 and Day 58. (A) Day 0 PBMC proliferation before immunization. (B) Day 30 (Boost) 
when calves received a boost immunization. (C) Day 44 (Pre-Challenge) PBMC proliferation 2 
weeks after calves received a boost. (D) Day 58 (Post-Challenge) PBMC proliferation 2 weeks 
after calves received an intravenous challenge of H. somni AVI1. Significance between non-
immunized and immunized were determined by parametric t-test (*=P<0.05, **=P≤0.01, 
***=P≤0.001). 
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5.6.2 Humoral responses following immunization with Receptor 1372, Tbp1 and 
Tbp2 
In order to determine if Receptor 1372, Tbp1 and Tbp2 induce a humoral immune response, 
the antibody titres were analyzed by serum ELISA. Serum was obtained from each animal as 
described above. The serum was used to determine the presence of antibodies specific to each 
protein. Antibody titres for each animal did not show an increase in antibody titres when exposed 
to Tbp1 (Figure 5-12A). This was as expected since Tbp1 is known to cause more of a cellular 
response while Tbp2 is known to cause more of a humoral response. A small increase in titres for 
immunized animals was observed though it was insignificant. Antibody titres to Tbp2 showed a 
significant increase when animals were immunized with the three proteins (Figure 5-12B). As seen 
in Figure 5-12C, there was not a significant increase in antibody response to Receptor 1372 in 
immunized animals that was expected based on the previous cattle trial. The antibody titres show 
that Tbp2 induces the humoral immune response, while Tbp1 and Receptor 1372 do not. The 
results of ELISA and proliferation assays confirm that Tbp1 causes more of a cellular response 
while Tbp2 causes a stronger humoral response. Receptor 1372 was shown to be immunogenic in 
the proliferation results however, these results and the antibody titres do not agree with the 
previous trial.  
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Figure 5-12 Serum titres from calves immunized with Receptor 1372, Tbp1 and Tbp2. Calves 
were immunized with Receptor 1372, Tbp1 and Tbp2. Serum samples were taken from immunized 
and non-immunized animals on Day 0, Boost (day 30), Pre-Challenge (day 44) and Post-Challenge 
(day 58). (A) Serum titres of antibodies specific for Tbp1. (B) Serum titres of antibodies specific 
for Tbp2. (C) Serum titres of antibodies specific for Receptor 1372. Significance between non-
immunized and immunized were determined by Mann-Whitney test (*=P<0.05, **=P≤0.01, 
***=P≤0.001). 
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6.0 GENERAL DISCUSSION AND CONCLUSIONS 
The BRD complex is an economically important disease caused by a number of agents such 
as viral and bacterial pathogens including H. somni [1-3]. H. somni causes both local and systemic 
infection with the incidence of systemic infection increasing over the past few decades. I 
hypothesized that vaccination with TonB-dependent proteins produced by H. somni would be 
protective against experimental infection and that a good cellular immune response is important 
for protection. Currently available vaccines that target H. somni are composed of killed whole cells 
using strains that were isolated decades ago. One exception is a bacterial extract vaccine consisting 
of in-vivo expressed antigens such as the IRPs. Based on this knowledge, the objectives of this 
study were to clone and express the genes coding for three TonB-dependent proteins and examine 
their effect on the humoral and cellular immune responses of cattle during experimental infection 
with H. somni. During this study, the work accomplished included: purification of Receptor 1372, 
Tbp1 and Tbp2, vaccination of cattle with Receptor 1372, characterisation of the humoral and 
cellular immune responses induced, vaccination of mice with Receptor 1372, Tbp1 and Tbp2 to 
determine if one or all of the proteins induce a cellular immune response and finally 
characterization of the immune responses and protective capacity in cattle of a vaccine containing 
Receptor 1372, Tbp1 and Tbp2.  
Receptor 1372, a heme/hemoglobin receptor family protein, is similar to the IRPs found in 
M. haemolytica, P. multocida and H. influenza [52-55]. Other than being a receptor and an iron-
regulated protein, the specific function of this receptor remains unclear and no examples of similar 
receptors were found. Receptor 1372 was cloned, expressed and purified using the vector 
pGH433His and E. coli DH5αFʼIQ. Once purified, I studied the cellular and humoral immune 
responses induced in mice followed by cattle. In mice, Receptor 1372 induced neither an increase 
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in IL-4, IL-5, or IFNγ production. In cattle, this protein was first tested by immunization with 
Receptor 1372 alone. The results of the cattle trial suggested that the receptor was immunogenic, 
inducing a strong increase in antibody production as well as a strong increase in PBMC 
proliferation. However, while combined with Tbp1 and Tbp2 in a subunit vaccine, Receptor 1372 
did not induce a cellular or a humoral response. This may have been due to the presence of Tbp1 
and/or Tbp2 interfering with the interaction of the receptor with host immune cells [79-81]. From 
this study, I was able to show that Receptor 1372 is capable of inducing both a cellular and a 
humoral immune response in cattle when it is the sole component of a vaccine. The fact that 
Receptor 1372 is iron-regulated and present in larger amounts when the bacterium is in an iron-
depleted environment, suggests that Receptor 1372 could be a candidate vaccine antigen against 
H. somni infection in cattle. Unfortunately, I was unable to determine if this receptor would be 
protective, as it would need further study with a second cattle trial. However, I am able to conclude 
that this IRP is immunogenic and immunization with Receptor 1372 results in an increase in 
PBMC proliferation as well as an increase in the production of Receptor 1372-specific antibodies.  
Transferrin and lactoferrin-binding proteins have been studied in Neisseriaceae, 
Moraxellaceae and Pasterellaceae such as Pasteurella multocida, Haemophilus influenzae, 
Neisseria gonnorrhoeae, Actinobacillus pleuropneumoniae and Neisseria meningitides [52-63]. 
Transferrin-binding protein 1 is equivalent to A. pleuropneumoniae and M. haemolytica’s, TbpA 
discussed previously. TbpA and Tbp1 are iron-regulated outer membrane receptor proteins 
involved in the uptake of iron [52-55]. These proteins tend to be expressed in larger amounts when 
in an environment depleted of iron making them good candidates to study the immune responses 
induced by H. somni antigens [65]. Previously, the use of TbpA from M. haemolytica and H. somni 
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in vaccines did not show evidence of an antibody response [63, 64]. It was hypothesized by Potter 
et al. that this may have been due to TbpA inducing primarily a cellular immune response [63].  
The tbp1 gene was cloned and Tbp1 expressed and purified using the MBP fusion vector, 
pMAL-c5X and E. coli ER2523. With the purified Tbp1, the immune responses induced were first 
studied in mice. In mice, immunization with Tbp1 did not result in an increase in production of 
humoral or cellular cytokines, IL-4/IL-5 and IFNγ, respectively. Next, the immunogenicity in 
cattle was tested by immunizing with a subunit vaccine containing Receptor 1372, Tbp1 and Tbp2. 
From this trial, I found that Tbp1 has the potential to be protective however; it may only be an 
ideal candidate for a vaccine if the goal is to induce a stronger cellular immune response. I was 
able to determine that Tbp1 does induce a significant cellular immune response shown by the 
increase in PBMC proliferation but it does not appear to have much impact on the humoral 
response, which agrees with the other studies of H. somni’s Tbp1 and M. haemolytica’s TbpA. 
Whether there is interference between Receptor 1372, Tbp1 and Tbp2 causing the low humoral 
response would need to be further evaluated. If a stronger cellular response were desired, Tbp1 
would be an ideal candidate vaccine antigen to include among others that induce a strong antibody 
response. This would ensure that the vaccine is stimulating two very important aspects of adaptive 
immunity. Since H. somni is an intracellular pathogen, it may be important to ensure cell-mediated 
immunity is primed while also priming for an antibody response to combat it before and after it 
enters immune cells. 
Transferrin-binding protein 2 is similar to TbpB of A. pleuropneumoniae and M. 
haemolytica, in that it is a co-factor to Tbp1, the main component of the iron-transport system in 
many species including H. influenza, P. multocida, M. haemolytica and Neisseria species [52-55]. 
As with Tbp1, Tbp2 has also been studied as a potential vaccine antigen. Previously, it was shown 
87 
 
that Tbp2 from H. somni induces a strong antibody response when used in the immunization of 
cattle [69]. It was also found that TbpB from M. haemolytica and many other species of bacteria 
induces a protective immune response and lessens the degree of disease, making it an ideal vaccine 
candidate [63]. 
As with Receptor 1372 and Tbp1, tbp2 was cloned and the protein expressed in various 
vectors and E. coli strains. When this was unsuccessful, Tbp2 was purified from a decades-old 
strain of H. somni, HS25. Previously, it had been cloned using the pGH433 vector and Tbp2 was 
purified by aggregate preparations. Once purified, the immune responses induced by Tbp2 were 
examined in mice, where Tbp2 was the only protein capable of inducing a cellular immune 
response observed by the increase in production of IFNγ. Once it was established that a response 
could be induced in mice by one of the three proteins, Tbp2 was combined in a subunit vaccine 
with Receptor 1372 and Tbp1 and used for the immunization of cattle. In cattle, it was found that 
Tbp2 induced a stronger humoral response than it did a cellular response. This finding agrees with 
other studies of a similar nature testing the protective capacity of Tbp2. Since Tbp2 is capable of 
inducing such a strong humoral response, it is a great candidate for vaccine use. From this study, 
I was able to conclude that Tbp2 is immunogenic in mice and cattle, inducing a stronger cellular 
response in mice and a stronger humoral response in cattle. The protective capacity of this protein 
would need to be studied further, perhaps on its own in a vaccine. 
Together, Tbp1 and Tbp2 play a central role in the pathogenesis of many species as 
described by Cornelissen et al. when they showed that a mutant N. gonorrhoeae deficient in a 
transferrin receptor was avirulent in humans [63, 82]. These transferrin-binding proteins have been 
shown to be protective antigens in some species including H. somni and M. haemolytica [63, 69]. 
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It is important to induce an antibody response when looking for a vaccine however, it may 
be time to consider the importance of a cellular immune response especially for intracellular 
pathogens. Since antibodies are useful in neutralizing and controlling extracellular pathogens, it is 
natural that this would be our main goal. However, H. somni has been found to survive and even 
impair the activities of multiple immune cells and this may indicate that it is necessary to look 
more closely at what cell-mediated immunity can do in the case of an H. somni infection. A vaccine 
capable of inducing a strong antibody response as well as inducing a protective cellular response 
may be important in combatting histophilosis in the cattle industry. The importance of the cellular 
immune response and the characterization of the cellular immune response to other H. somni 
antigens would need to be further studied in order to understand more about this disease.   
In conclusion, based on the results of the murine trial and both cattle trials, Receptor 1372, 
Tbp1 and Tbp2 proved to be immunogenic in cattle as they induced either a cellular or a humoral 
response. In the case of Receptor 1372, it was capable of inducing both a strong cellular and a 
strong humoral response in cattle, suggesting it may be a good candidate vaccine antigen. In cattle, 
Tbp1 and Tbp2 were capable of inducing either a stronger humoral response or a stronger cellular 
response respectively and this may need to be taken into consideration when selecting vaccine 
candidates. In mice, only Tbp2 proved to be immunogenic by inducing a significant increase in 
the cellular immune response. Whether these proteins are protective would need to be studied 
further with a trial involving the immunization of cattle with Receptor 1372, Tbp1 and Tbp2.   
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